

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risk factors, risk stratification and risk-specific surveillance strategies after endovascular aneurysm repair: Study protocol for a Delphi study by the International Risk Stratification in EVAR (IRIS- EVAR) working group

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055803
Article Type:	Protocol
Date Submitted by the Author:	31-Jul-2021
Complete List of Authors:	Antoniou, George A.; Royal Oldham Hospital, Department of Vascular & Endovascular Surgery Schermerhorn , Marc L. ; Beth Israel Deaconess Medical Center and Harvard Medical School Forbes, Thomas; Peter Munk Cardiac Centre, Division of Vascular Surgery Cheng, Vincent; University of Bristol , Bristol Medical School Antoniou, Stavros; Mediterranean Hospital of Cyprus, Golledge, Jonathan; James Cook University Queensland Research Centre for Peripheral Vascular Disease, Vascular Biology Unit; Townsville Hospital and Health Service, Department of Vascular and Endovascular Surgery, The Townsville Hospital, Queensland, Australia Verhagen, H; Erasmus Universiteit Rotterdam, Torella, Francesco; Liverpool University Hospitals NHS Foundation Trust, Liverpool vascular & Endovascular Service; University of Liverpool, School of Physical Sciences
Keywords:	VASCULAR SURGERY, Adult surgery < SURGERY, ULTRASONOGRAPHY, Computed tomography < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

1
2
3 **Risk factors, risk stratification and risk-specific surveillance strategies after endovascular aneurysm**
4 **repair: Study protocol for a Delphi study by the International Risk Stratification in EVAR (IRIS-**
5 **EVAR) working group**
6
7
8
9
10
11
12
13

14 ^{1,2}George A. Antoniou MD, PhD, MSc, FEBVS

17 ³Marc L. Schermerhorn MD

20 ⁴Thomas L. Forbes MD

23 ⁵Vincent Cheng BSc, MSc, PGDiP, DPhil

26 ^{6,7}Stavros A. Antoniou MD, PhD, MPH, FEBS, FACS

29 ^{8,9,10}Jonathan Golledge MB BChir, MA, FRCS, FRACS, MChir

32 ¹¹Hence J.M. Verhagen MD, PhD

35 ^{12,13,14}Francesco Torella MD, FRCS

38
39
40
41
42
43 ¹Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute
44 Hospitals NHS Trust, Northern Care Alliance NHS Group, Manchester, United Kingdom

47
48
49 ²Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester,
50 Manchester, United Kingdom

51
52
53
54 ³Divisions of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston,
55 Mass, United States of America
56
57
58
59
60

1
2
3 ⁴Division of Vascular Surgery, Peter Munk Cardiac Centre and University Health Network, University
4
5 of Toronto, Toronto, Ontario, Canada
6
7

8 ⁵Bristol Medical School, University of Bristol, Bristol, United Kingdom
9
10

11 ⁶Medical School, European University of Cyprus, Nicosia, Cyprus
12
13

14 ⁷Department of Surgery, Mediterranean Hospital of Cyprus, Limassol, Cyprus
15
16

17 ⁸Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry,
18
19 James Cook University, Townsville, Australia
20
21

22 ⁹Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville,
23
24 Australia
25
26

27 ¹⁰Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia
28
29

30 ¹¹Division of Vascular and Endovascular Surgery, Erasmus University Medical Centre, Rotterdam, The
31
32 Netherlands.
33
34

35 ¹²Liverpool Vascular & Endovascular Service, Liverpool, United Kingdom
36
37

38 ¹³School of Physical Sciences, University of Liverpool, Liverpool, United Kingdom
39
40

41 ¹⁴Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
42
43
44
45
46
47
48
49
50

51 **Corresponding author:** Professor Francesco Torella
52

53
54 Address: Liverpool University Hospitals NHS Foundation Trust, Liverpool Vascular & Endovascular
55
56 Service, Prescot Street, Liverpool, UK L7 8XP. Email: f.torella@liv.ac.uk
57
58

59 **ABSTRACT**
60

1
2
3 **Introduction:** Several risk factors for adverse events after endovascular aneurysm repair (EVAR) have
4
5 been described, but there is no consensus on their comparative prognostic significance, use in risk
6
7 stratification and application in determining postoperative surveillance.
8
9

10
11 **Methods and analysis:** A scoping review of the literature was conducted to identify risk factors for
12
13 adverse events after EVAR. Main adverse events were considered post-EVAR abdominal aortic
14
15 aneurysm rupture and reintervention. Risk factors were grouped into four domains: 1) preoperative
16
17 anatomy, 2) aortic device, 3) procedure performance, and 4) postoperative surveillance. The Delphi
18
19 methodology will be used to steer a group of experts in the field towards consensus organised into
20
21 three tiers. In tier 1, participants will be asked to independently rate risk factors for adverse events
22
23 after EVAR. In tier 2, the panel will be asked to independently rate a range of combinations of risk
24
25 factors across the four domains derived from tier 1. A risk-stratification tool will then be built, which
26
27 will include algorithms that map responses to signalling questions onto a proposed risk judgement
28
29 for each domain. Domain-level judgements will in turn provide the basis for an overall risk
30
31 judgement for the individual patient. In tier 3, risk factor-informed surveillance strategies will be
32
33 developed. Each tier will typically include three rounds and rating will be conducted using a four-
34
35 point Likert scale, with an option for free text responses.
36
37
38
39
40

41 **Ethics and dissemination:** Research Ethics Committee and Health Research Authority approval has
42
43 been waived, since this is a professional staff study and no duty of care lies with the NHS to any of
44
45 the participants. The results will be presented at regional, national and international meetings, and
46
47 will be submitted for publication in peer-reviewed journals. The risk stratification tool and
48
49 surveillance algorithms will be made publicly available for clinical use and validation.
50
51
52
53
54
55
56
57
58
59

60 **Strengths and limitations of this study**

- 1
2
3 1. This is the first study to apply a structured, systematic, interactive, forecasting Delphi
4 methodology to steer a multidisciplinary group of experts in the field of endovascular
5 aneurysm repair (EVAR) towards consensus.
6
7
- 8
9
10
11 2. This study aims to identify the most important and clinically relevant risk factors for adverse
12 events (i.e. abdominal aortic aneurysm rupture and reintervention) after EVAR, develop risk
13 stratification models, and propose risk factor-specific surveillance strategies.
14
15
- 16
17
18 3. This study has the potential to provide an evidence and expert opinion informed risk
19 stratification tool for use in clinical practice.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

1
2
3 Abdominal aortic aneurysm (AAA) is an important cause of death in older adults. The only
4 established treatments for AAA are endovascular aneurysm repair (EVAR) or open surgical repair.
5
6 EVAR is a less invasive treatment with lower perioperative mortality, shorter hospital stay and
7
8 quicker recovery than open surgical repair. EVAR, however, has inferior long-term outcomes than
9
10 open surgical repair, including increased risk of aneurysm rupture, secondary intervention and
11
12 aneurysm-related mortality.¹⁻³ In order to select the most appropriate AAA treatment, clinicians
13
14 need to consider AAA rupture risk, perioperative risk and durability of treatment.
15
16
17
18
19

20 Several risk factors for adverse events following EVAR, including post-EVAR AAA rupture and
21
22 reintervention, have been identified, such as hostile aortic anatomy and postoperative AAA
23
24 growth.^{4,5} Risk factors have the potential to inform decision making and tailor management to
25
26 individual patients, optimise perioperative care and customise surveillance, with a view to mitigating
27
28 the risk of complications. Prior research has been conducted in developing risk stratification tools in
29
30 the setting of standard EVAR, which has mostly considered preoperative clinical and morphological
31
32 factors.⁶⁻⁹ Such risk models have had little impact and utility in clinical practice and many are
33
34 obsolete, since they were developed based on old generation aortic devices, practices and
35
36 technologies. Prior research suggests that risk factors for complications after EVAR can be grouped
37
38 into four domains: 1) preoperative anatomy, 2) aortic device, 3) procedure performance, and 4)
39
40 postoperative surveillance.¹⁰ No previous research has investigated the significance of parameters
41
42 from across all four domains in risk prediction modelling and stratification. Furthermore, no previous
43
44 studies have developed an expert consensus informed risk stratification incorporating a combination
45
46 of such factors.
47
48
49
50
51

52 It is unlikely that risk stratification systems including all variables from the aforementioned
53
54 domains will be developed within randomized clinical trials, because of logistical difficulties with
55
56 recruiting large numbers of patients and long-term follow-up.¹¹ Similar difficulties may be
57
58 encountered with well designed and executed prospective cohort and registry studies, which would
59
60

1
2
3 need a long follow-up to provide robust knowledge on surveillance strategies in EVAR, that may be
4
5 of little use in light of the constantly evolving endovascular practices and technologies. Given the
6
7 current uncertainty surrounding risk stratification and the variability in follow-up routines in EVAR, a
8
9 structured, systematic, interactive, forecasting Delphi approach using expert opinions may enable
10
11 the development of an appropriate tool that can inform clinical practice.
12
13

14
15 In this study, the Delphi methodology will be used to develop a consensus of expert
16
17 opinions. The objective is to identify the most important and clinically relevant risk factors for
18
19 adverse events (i.e. abdominal aortic aneurysm rupture and reintervention) after EVAR, develop risk
20
21 stratification models, and propose risk factor-specific surveillance strategies.
22
23

24 25 **METHODS**

26 27 **Setting the forecasting task**

28
29 A scoping literature review was conducted on PubMed/MEDLINE from inception of EVAR to the
30
31 present date to identify prognostic studies investigating the prognostic value of anatomical,
32
33 procedural and surveillance parameters in standard EVAR. The focus of the literature search was to
34
35 identify risk factors which may usefully inform surveillance strategies to mitigate the risk of adverse
36
37 clinical outcomes, such as post-EVAR AAA rupture and secondary intervention. Two authors
38
39 screened reports and confirmed eligibility of studies. Preoperative, intraoperative, procedural and
40
41 postoperative imaging risk factors predictive of outcome after standard EVAR were listed and
42
43 defined. Such parameters were summarized in a table and a qualitative analysis was undertaken
44
45 (Table 1). The published evidence has been previously assessed using the GRADE (Grading of
46
47 Recommendations, Assessment, Development and Evaluation) framework.^{5,12,13}
48
49
50
51
52
53
54

55 In light of the low quality evidence on and lack of clarity over the comparative prognostic
56
57 significance of prognostic factors, their use in risk stratification and their impact on modes and
58
59
60

1
2
3 strategies of follow-up in the setting of EVAR,¹⁴ the Delphi methodology will be used to steer a group
4
5 of experts in the field towards consensus.¹⁵
6
7

8 **Steering committee, facilitators and expert panel** 9

10
11 The Delphi task will be conducted by the following three distinct groups:
12
13

- 14 1. Steering committee
- 15
16 2. Facilitators
- 17
18 3. Expert Delphi committee
19
20
21
22

23
24 The role of the steering committee will be to analyse and appraise the available evidence,
25 design the Delphi study, analyse the Delphi participant responses, agree on risk stratification
26 system(s) and surveillance strategies (that will be developed based on consensus from the expert
27 Delphi committee), and propose areas for future research. The steering committee are an
28 interdisciplinary group consisting of vascular surgeons and endovascular specialists, and experts in
29 outreach, knowledge and evidence search and synthesis.
30
31
32
33
34
35
36
37
38

39 The facilitators are two members of the steering committee who will supervise the process
40 and communicate between the steering committee and the Delphi panel. They will be responsible
41 for the design and administration of the iterative Delphi process. The facilitators will formulate the
42 survey questions, disseminate the questions via the Delphi platform, facilitate the responses of and
43 provide feedback to the panel experts, and generate the final forecasts.
44
45
46
47
48
49

50
51 The composition and size of the expert Delphi panel will be decided by the steering
52 committee. Delphi panellists will be selected based on specialist knowledge, qualifications and a
53 proven track record in the field. Expertise will be defined by relevant publications, successful
54 relevant research grant applications or membership in relevant guideline committees. Clinical and
55
56
57
58
59
60

1
2
3 policy development experience will also be considered. International experts will be included to
4
5 account for variability in clinical practices and ensure group dynamics in reaching consensus. A
6
7 varied panel will be selected ensuring geographical, sex and age diversity.¹⁶ Vascular surgeons,
8
9 interventional radiologists, other clinicians dealing with vascular disease (e.g. angiologists and
10
11 interventional cardiologists), EVAR surveillance coordinators and vascular nurse specialists will be
12
13 considered. Fifty experts will be invited via e-mail to participate in the Delphi panel. A reminder will
14
15 be sent via e-mail a week after the first invite, in case of no response. A minimum of 35 Delphi
16
17 members will be required to reach consensus.
18
19

20
21
22 Delphi panellists will be fluent in English and be affiliated with an academic or health service
23
24 institution. All experts will have an equal contribution, i.e. equal voting. To complete the Delphi
25
26 process, participants will be required to respond across all rounds. Those who do not respond in the
27
28 first round will not be invited to participate in subsequent rounds. Baseline demographics (age,
29
30 gender), country of residence, current role (consultant, trainee doctor, other health professional),
31
32 academic degree(s) and duration of experience in the field will be recorded at the start of the
33
34 survey.
35
36

37
38
39 Anticipated difficulties with continued commitment and engagement of Delphi members in
40
41 the process will be addressed by careful selection of national and international experts with a
42
43 demonstrated interest in the field. Our objective is to build a coherent team working collaboratively
44
45 towards consensus within the iterative Delphi process. Collaborative group authorship will be
46
47 offered to incentivise participating members.
48
49

50 51 **Questionnaires/surveys**

52
53
54 The entire project will comprise of three tiers (Figure 1). Each tier will constitute a distinct Delphi
55
56 process, which is aimed to include three rounds, unless consensus is achieved earlier in the
57
58 process.¹⁷ Attempts will be made to have the same Delphi panel in all three tiers, but the
59
60

1
2
3 composition of the panel is expected to vary between the tiers, depending on the availability and
4
5 willingness of Delphi experts to participate in all three Delphi processes. Examples of planned Delphi
6
7 surveys are presented in Appendix 1-3.
8
9

10 **Tier 1**

11
12
13
14 In tier 1, participants will be asked to independently rate individual proposed risk factors for adverse
15
16 events after standard EVAR with infra-renal devices across four distinct domains: 1) preoperative
17
18 anatomical factors, 2) aortic device-related factors, 3) intraoperative/procedure-related factors, and
19
20 4) postoperative surveillance imaging factors (Table 1, Appendix 1). The adverse events of interest
21
22 are post-EVAR AAA rupture and reintervention. The risk factors have been identified during the
23
24 literature search. Risk factors that are deemed the most consistently identified will be selected by
25
26 the steering committee. The focus of the expert Delphi panel will be directed towards the
27
28 importance of including such factors in risk stratification following EVAR with a view to developing
29
30 risk-specific surveillance algorithms.
31
32
33
34

35
36 The rating will be conducted using a four-point Likert scale, i.e. “strongly agree”, “agree”,
37
38 “disagree” and “strongly disagree”.¹⁸ For each item, participants will be given the option to select
39
40 “can’t say” as an alternative response to reflect neutrality. A free-text response within each domain
41
42 will be available to participants, providing the opportunity to suggest additional risk factors and
43
44 elaborate on their responses. Additional risk factors suggested by Delphi panel members will be
45
46 considered by the steering committee for inclusion in the subsequent Delphi rounds. If responders
47
48 “strongly agree” or “agree” with a specific risk factor being an important predictor of adverse events
49
50 after EVAR, it will be considered in risk stratification and surveillance strategies. The participant will
51
52 then be asked to stratify the importance of this factor in surveillance tailoring by choosing one of the
53
54 following options: “high importance”, “medium importance” or “low importance”. The Delphi round
55
56 will be repeated until consensus is reached. Feedback to the experts will include summary statistics
57
58 and outlines of qualitative justifications.
59
60

Tier 2

In tier 2, the Delphi panel will be asked to independently rate a range of combinations of risk factors across the four domains. The risk factors will be those that were agreed upon in tier 1. The importance of individual risk factors, as agreed upon in tier 1, will be considered in stratifying the risk in individual domains. Based on the chosen risk factor combination, the risk for the specific domain will be stratified as low or high. Then, consensus will be sought on stratifying the overall risk as “low”, “intermediate” or “high” based on combinations of domain-specific risks (Appendix 2). The questionnaire will be supplemented by a graphical summary of risk stratification models, which will provide the Delphi participants with a list of risk factors, their importance and all possible combinations to stratify domain-specific and overall risks (Figure 2).

The same methodology as that applied in tier 1 will be used, i.e. a four-point Likert scale, “can’t say” option and free text response. Suggestions made by Delphi panel members about stratifying risk in specific domains will be considered for inclusion in subsequent Delphi rounds. The Delphi process will be repeated until consensus is reached. Feedback will also comprise graphical presentations of findings.

Tier 3

The aim of tier 3 will be to develop risk-specific surveillance strategies. The survey will consist of a combination of open-ended and close-ended questions concerning EVAR surveillance (Appendix 3). Consensus will be sought on the following:

1. Whether the same surveillance strategy should be applied in low, intermediate and high-risk patient groups (as defined in tier 2) or a specific surveillance strategy for low risk patients and another strategy for intermediate and high-risk patients is needed.

- 2.
2. Surveillance imaging modes (ultrasonography, computed tomography, plain X-ray or a combination) and intervals (or time points) when surveillance imaging should be undertaken.

Specific questions will be asked on the role of contrast enhanced ultrasonography and digital subtraction angiography in EVAR surveillance. Furthermore, consensus will be sought on the threshold of sac expansion and graft migration that should trigger further investigations and/or interventions. Answers to such open-ended questions will be analysed applying descriptive statistics to reach consensus (Appendix 3).

Expert participants will be asked to judge questions using the methodology presented in tier 1 and 2. Similar to Tier 1 and 2, suggestions made by Delphi panellists about surveillance strategies for specific risk categories will be considered for inclusion in subsequent Delphi rounds. Delphi rounds will be repeated until consensus is achieved. Feedback to the expert Delphi panel will include a statistical summary, a summary of qualitative responses and graphical presentations of surveillance algorithms.

Risk stratification tool

The risk stratification tool will be based on identified and agreed risk factors, will provide a framework for considering the risk of adverse events, e.g. AAA rupture or reintervention, after standard EVAR, and will guide tailored (or risk-specific) surveillance algorithms. The tool will be structured into four domains, each consisting of distinct risk factors, and will be based on consensus achieved in tier 1 and 2:

1. Preoperative anatomy
2. Aortic device
3. Procedure performance

4. Early surveillance

Signalling questions for individual risk factors within each domain will be answered with the response options “yes” or “no”. An example of a signalling question is: “*Is the length of the proximal aortic neck >15 mm?*”. The tool will provide space for free text alongside the signalling question, e.g. for the clinician to provide a specific numerical value for the length of the proximal aortic neck.

The risk stratification tool will be conceived hierarchically: responses to signalling questions will provide the basis for domain-level judgements about the risk of adverse events following EVAR (low risk or high risk). In turn, these domain-level judgements will provide the basis for an overall risk judgement for the individual patient being assessed. The tool will include algorithms that map responses to signalling questions onto a proposed risk judgement for each domain. The possible risk judgements are:

1. Low risk
2. Intermediate risk
3. High risk

The algorithms will provide proposed judgements, but users will be able to verify these and change them if they feel this is appropriate. An online tool (web application) for clinical guide and validation is planned.

Data analysis

The Bristol Online Surveys tool, which is an online tool designed for academic research, educational and public sector organisations, will be used for the Delphi survey platform.¹⁹ Descriptive statistics will be applied to describe characteristics of the Delphi panel participants and group responses to each statement in all three rounds. Cronbach’s alpha will be used to determine the internal

1
2
3 consistency of the assessment tool after each round. Consensus will be defined as >70% of
4
5 participants agreeing/strongly agreeing or disagreeing/strongly disagreeing with a statement in each
6
7 round.²⁰ “Can’t say” responses will be excluded from the analyses to ensure that only responses
8
9 from experts who felt confident about their response are taken into account. If consensus is not
10
11 reached on one or more of the survey items at the end of each Delphi process, the steering
12
13 committee will consider the Delphi expert responses and decide on the most appropriate or popular
14
15 answers to the survey questions. An explicit statement that no consensus has been reached will be
16
17 added to the risk stratification tools/surveillance algorithms. Analyses will be conducted using SPSS
18
19 for windows.
20
21
22

23 24 **Patient and public involvement**

25
26
27 The opinions of two patient advocates with personal experience in abdominal aortic aneurysm
28
29 treatment on surveillance algorithms proposed by the expert Delphi panel will be considered in Tier
30
31 3. Patient advocates are expected to provide their perspectives on feasibility and ease of
32
33 surveillance modes and strategies, patient experience, and potential impact on quality of life, and
34
35 make suggestions for optimisation of such practices. Such opinions will be reviewed by the steering
36
37 committee and presented in the final document.
38
39
40

41 42 **ETHICS AND DISSEMINATION**

43
44
45 Research Ethics Committee and Health Research Authority approval is waived, since this is a
46
47 professional staff study and no duty of care lies with the NHS (National Health Service) to any of the
48
49 participants. The study is anticipated to start as soon as the study protocol is published online in a
50
51 peer-reviewed journal. The published study protocol will be sent to Delphi members along with the
52
53 inviting letter. Electronic informed consent will be requested from Delphi participants at the start of
54
55 round 1 of each Delphi process (tier). The Delphi processes for all three tiers are anticipated to be
56
57 completed within 12 months from the date of the first invitation. The participating Delphi experts
58
59
60

1
2
3 will remain anonymous during the entire process. The results of the study will be published (with the
4 names of all participating Delphi members) after all three Delphi processes have been completed. All
5 data will be handled in accordance with UK data protection regulations.
6
7
8
9

10 Information on conflict of interest will be obtained from steering committee members and
11 Delphi panel participants. Potential conflicts of interest will be dealt with by re-assigning functions or
12 replacing participants who pose interest conflict.
13
14
15
16
17

18 The results of the study will be presented at regional, national and international meetings.
19 The study findings will also be published in peer-reviewed journals. The Delphi panel's contribution
20 will be acknowledged by group authorship in peer-reviewed publications. Dissemination will also
21 occur through social media and other collaboration tools.
22
23
24
25
26
27

28 **Authors' contributions:**
29

30
31 George A. Antoniou: Conception, design, literature search and analysis, interpretation of data,
32 drafting the study protocol, approval.
33
34

35
36
37 Marc L. Schermerhorn: Design, interpretation of data, critical revision, approval.
38

39
40 Thomas L. Forbes: Design, interpretation of data, critical revision, approval.
41

42
43 Vincent Cheng: Design, critical revision, approval.
44
45

46
47 Stavros A. Antoniou: Conception, design, literature search and analysis, interpretation of data,
48 drafting the study protocol, critical revision, approval.
49
50

51
52 Jonathan Golledge: Design, interpretation of data, critical revision, approval.
53

54
55 Hence J.M. Verhagen: Design, interpretation of data, critical revision, approval.
56
57
58
59
60

1
2
3 Francesco Torella: Conception, design, literature analysis, interpretation of data, critical revision,
4 approval.
5
6
7
8
9
10

11 **Funding statement:** No funding has been obtained for this work.
12
13
14
15
16
17

18 **Competing interests statement:** Hence J.M. Verhagen has conflicts of interest with Medtronic, WL
19 Gore, Abbott, Endologix and Arsenal AAA. The rest of the authors have no conflicts of interest to
20 declare.
21
22
23
24
25
26
27
28

29 REFERENCES

- 30
31
32
33 1. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM; EVAR trial investigators. Endovascular
34 versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK
35 endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. *Lancet*.
36 2016;388:2366-2374.
37
38
39
40
41
42 2. Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT Jr, Matsumura JS, Huo Z,
43 Johnson GR; OVER Veterans Affairs Cooperative Study Group. Open versus endovascular
44 repair of abdominal aortic aneurysm. *N Engl J Med*. 2019;380:2126-2135.
45
46
47
48
49
50 3. Antoniou GA, Antoniou SA, Torella F. Endovascular vs. open repair for abdominal aortic
51 aneurysm: Systematic review and meta-analysis of updated peri-operative and long term
52 rata of randomised controlled trials. *Eur J Vasc Endovasc Surg*. 2020;59:385-397.
53
54
55
56
57
58
59
60

- 1
2
3 4. Antoniou GA, Georgiadis GS, Antoniou SA, Kuhan G, Murray D. A meta-analysis of outcomes
4
5 of endovascular abdominal aortic aneurysm repair in patients with hostile and friendly neck
6
7 anatomy. *J Vasc Surg.* 2013;57:527-38.
8
9
- 10
11 5. Antoniou GA, Alfahad A, Antoniou SA, Torella F. Prognostic significance of aneurysm sac
12
13 shrinkage after endovascular aneurysm repair. *J Endovasc Ther.* 2020;27:857-868.
14
15
- 16
17 6. Karthikesalingam A, Holt PJ, Vidal-Diez A, Choke EC, Patterson BO, Thompson LJ, Ghatwary T,
18
19 Bown MJ, Sayers RD, Thompson MM. Predicting aortic complications after endovascular
20
21 aneurysm repair. *Br J Surg.* 2013;100:1302-11.
22
23
- 24
25 7. Png CYM, Tadros RO, Beckerman WE, Han DK, Tardiff ML, Torres MR, Marin ML, Faries PL.
26
27 An anatomic risk model to screen post endovascular aneurysm repair patients for aneurysm
28
29 sac enlargement. *J Surg Res.* 2017;217:29-35.e1.
30
31
- 32
33 8. Barnes M, Boulton M, Maddern G, Fitridge R. A model to predict outcomes for endovascular
34
35 aneurysm repair using preoperative variables. *Eur J Vasc Endovasc Surg.* 2008;35(5):571-9.
36
37
- 38
39 9. Chaikof EL, Fillinger MF, Matsumura JS, Rutherford RB, White GH, Blankensteijn JD, Bernhard
40
41 VM, Harris PL, Kent KC, May J, Veith FJ, Zarins CK. Identifying and grading factors that modify
42
43 the outcome of endovascular aortic aneurysm repair. *J Vasc Surg.* 2002;35(5):1061-6.
44
45
- 46
47 10. Antoniou GA. Risk stratification and risk-specific surveillance for endovascular aneurysm
48
49 repair. *Eur J Vasc Endovasc Surg.* DOI:<https://doi.org/10.1016/j.ejvs.2020.08.049>.
50
51
- 52
53 11. Wanhainen A. Response to "Re 'European Society for Vascular Surgery (ESVS) 2019 Clinical
54
55 Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms'". *Eur J*
56
57 *Vasc Endovasc Surg.* 2020;60(6):951
58
59
60

12. Antoniou GA, Juszczak MT, Nasr H, Narlawar R, Antoniou SA, Matsagkas M, Donas KP, de Vries JPM. Prognosis review and time-to-event data meta-analysis of endovascular aneurysm repair outside versus within instructions for use of aortic endograft devices. *J Vasc Surg.* 2020;71:1415-1431.e15.
13. Antoniou GA, Alfahad A, Antoniou SA, Badri H. Prognostic significance of large diameter proximal aortic neck in endovascular aneurysm repair. *Vasa.* 2020;49:215-224.
14. Patel SR, Allen C, Grima MJ, Brownrigg JRW, Patterson BO, Holt PJE, Thompson MM, Karthikesalingam A. A systematic review of predictors of reintervention after EVAR: Guidance for risk-stratified surveillance. *Vasc Endovascular Surg.* 2017;51:417-428.
15. Jones J and Hunter D. Consensus methods for medical and health services research. *BMJ.* 1995;311:376-80.
16. Yancik R and Maklan CW. The Delphi method as a research tool in gerontological curriculum planning. *Gerontol Geriatr Educ.* Spring 1981;1:163-8.
17. Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. *BMC Med Res Methodol.* 2005;5:37.
18. Iqbal S, Pison-Young L. The Delphi method. *Psychologist.* 2009;22:598-600.
19. Bristol Online Surveys. <https://www.onlinesurveys.ac.uk/>.
20. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, Wales PW. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol.* 2014;67:401-9.

<p>Preoperative anatomy</p> <ul style="list-style-type: none"> • proximal aortic neck length >15 mm • proximal aortic neck diameter <30 mm • infra-renal angulation <60 degrees • supra-renal angulation <45 degrees • <50% circumferential proximal neck calcification • <50% circumferential proximal neck thrombus • non-conical proximal aortic neck • maximal AAA diameter <70 mm • ≤2 patent lumbar arteries plus non-patent IMA or ≤1 patent lumbar artery plus patent IMA • distal aortic neck diameter >18 mm • no common iliac artery aneurysm^a • distal iliac landing zone diameter <20 mm • distal iliac landing zone length >10 mm • iliac tortuosity index <1.25^b
<p>Aortic device</p> <ul style="list-style-type: none"> • anatomy complaint with IFU • supra-renal fixation device • infra-renal fixation device • EVAR procedure performed according to IFU
<p>Procedure performance</p> <ul style="list-style-type: none"> • good position of endografts in relation to distal, overlapping, and proximal landing zones • no non-type II endoleak/kink/stenosis on completion angiogram • no unplanned adjunctive procedures in the proximal neck • no unplanned adjunctive procedure other than in the proximal neck
<p>Postoperative surveillance</p> <ul style="list-style-type: none"> • satisfactory seal at landing/overlapping zones • no endoleak (type II) • sac shrinkage^c • no sac expansion^c

^adefined as diameter >25 mm

^bcalculated by dividing the distance along the central lumen line from the aortic bifurcation to the common femoral artery by the straight-line distance from the aortic bifurcation to the common femoral artery. A ratio of < 1.25 is optimal while a ratio of > 1.6 is deemed as severe.

^csac expansion or sac shrinkage is defined as a 5 mm increase or decrease in the size of the abdominal aortic aneurysm sac between two surveillance imaging tests of the same mode occurring during any time period.

Table 1. Prognostic factors of endovascular aneurysm repair that should be considered in risk stratification and surveillance strategies. AAA, abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; IFU, instructions for use; IMA, inferior mesenteric artery.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

1 Structure of the study

2 Risk stratification model

For peer review only



Structure of the study

178x139mm (72 x 72 DPI)



Risk stratification model

333x198mm (72 x 72 DPI)

Domain 1 – Preoperative anatomy

Is "*proximal aortic neck length <15 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*proximal aortic neck diameter >30 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*infra-renal neck angulation >60 degrees*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

1
2
3
4 Is "*supra-renal neck angulation >45 degrees*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

- 5
6 1. Strongly agree
7 2. Agree
8 3. Disagree
9 4. Strongly disagree
10 5. Can't say

11 Comments/suggestions:

12
13 If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

- 14
15 1. High importance
16 2. Medium importance
17 3. Low importance

18
19
20
21
22 Is "*>50% circumferential proximal aortic neck calcification*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

- 23
24 1. Strongly agree
25 2. Agree
26 3. Disagree
27 4. Strongly disagree
28 5. Can't say

29 Comments/suggestions:

30
31 If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

- 32
33 1. High importance
34 2. Medium importance
35 3. Low importance

36
37
38
39
40 Is "*>50% circumferential proximal aortic neck thrombus*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

- 41
42 1. Strongly agree
43 2. Agree
44 3. Disagree
45 4. Strongly disagree
46 5. Can't say

47 Comments/suggestions:

48
49 If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

- 50
51 1. High importance
52 2. Medium importance
53 3. Low importance

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Is "*conical proximal aortic neck*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*maximal AAA diameter >70 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*>2 patent lumbar arteries plus non-patent IMA or >1 patent lumbar artery plus patent IMA*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Is "*distal aortic neck diameter <18 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*common iliac artery aneurysm (if common iliac artery used as a landing zone)*"^a an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*distal iliac landing zone diameter >20 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

1
2
3
4 Is "*distal iliac landing zone length <10 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

- 5
6 1. Strongly agree
7 2. Agree
8 3. Disagree
9 4. Strongly disagree
10 5. Can't say

11 Comments/suggestions:

12 If you strongly agree or agree with the statement, how would you stratify the importance of the
13 predictor within the context of risk stratification and surveillance strategies?

- 14 1. High importance
15 2. Medium importance
16 3. Low importance

17
18
19
20
21 Is "*iliac tortuosity index >1.25*"^b an important predictor of adverse events after EVAR that should
22 be considered in risk stratification and surveillance strategies?

- 23 1. Strongly agree
24 2. Agree
25 3. Disagree
26 4. Strongly disagree
27 5. Can't say

28 Comments/suggestions:

29
30 If you strongly agree or agree with the statement, how would you stratify the importance of the
31 predictor within the context of risk stratification and surveillance strategies?

- 32 1. High importance
33 2. Medium importance
34 3. Low importance

35
36
37
38
39 Would you suggest any other preoperative anatomy-related predictors of adverse outcomes after
40 EVAR?

41
42
43 **Domain 2 - Aortic device**

44 Is "*anatomy non-complaint with IFU*" an important predictor of adverse events after EVAR that
45 should be considered in risk stratification and surveillance strategies?

- 46 1. Strongly agree
47 2. Agree
48 3. Disagree
49 4. Strongly disagree
50 5. Can't say

51 Comments/suggestions:

52
53 If you strongly agree or agree with the statement, how would you stratify the importance of the
54 predictor within the context of risk stratification and surveillance strategies?

- 55 1. High importance
56 2. Medium importance
57 3. Low importance

58
59 Is "*supra-renal fixation device*" an important predictor of adverse events after EVAR that should
60 be considered in risk stratification and surveillance strategies?

1	1. Strongly agree
2	2. Agree
3	3. Disagree
4	4. Strongly disagree
5	5. Can't say
6	Comments/suggestions:
7	If you strongly agree or agree with the statement, how would you stratify the importance of the
8	predictor within the context of risk stratification and surveillance strategies?
9	1. High importance
10	2. Medium importance
11	3. Low importance
12	Is " <i>infra-renal fixation device</i> " an important predictor of adverse events after EVAR that should be
13	considered in risk stratification and surveillance strategies?
14	1. Strongly agree
15	2. Agree
16	3. Disagree
17	4. Strongly disagree
18	5. Can't say
19	Comments/suggestions:
20	If you strongly agree or agree with the statement, how would you stratify the importance of the
21	predictor within the context of risk stratification and surveillance strategies?
22	1. High importance
23	2. Medium importance
24	3. Low importance
25	Is " <i>EVAR procedure not performed according to IFU</i> " an important predictor of adverse events
26	after EVAR that should be considered in risk stratification and surveillance strategies?
27	1. Strongly agree
28	2. Agree
29	3. Disagree
30	4. Strongly disagree
31	5. Can't say
32	Comments/suggestions:
33	If you strongly agree or agree with the statement, how would you stratify the importance of the
34	predictor within the context of risk stratification and surveillance strategies?
35	1. High importance
36	2. Medium importance
37	3. Low importance
38	Would you suggest any other aortic device-related predictors of adverse outcomes after EVAR?
39	
40	Domain 3 - Procedure performance
41	Is " <i>suboptimal position of endografts in relation to distal, overlapping, and proximal landing</i>
42	<i>zones</i> " an important predictor of adverse events after EVAR that should be considered in risk
43	stratification and surveillance strategies?
44	1. Strongly agree
45	2. Agree
46	3. Disagree
47	4. Strongly disagree
48	5. Can't say
49	Comments/suggestions:
50	If you strongly agree or agree with the statement, how would you stratify the importance of the
51	predictor within the context of risk stratification and surveillance strategies?

1	1. High importance
2	2. Medium importance
3	3. Low importance
4	
5	
6	
7	Is “ <i>non-type II endoleak/kink/stenosis on completion angiogram</i> ” an important predictor of
8	adverse events after EVAR that should be considered in risk stratification and surveillance
9	strategies?
10	1. Strongly agree
11	2. Agree
12	3. Disagree
13	4. Strongly disagree
14	5. Can't say
15	Comments/suggestions:
16	
17	If you strongly agree or agree with the statement, how would you stratify the importance of the
18	predictor within the context of risk stratification and surveillance strategies?
19	1. High importance
20	2. Medium importance
21	3. Low importance
22	
23	Is “ <i>unplanned adjunctive procedures in the proximal neck</i> ” an important predictor of adverse
24	events after EVAR that should be considered in risk stratification and surveillance strategies?
25	1. Strongly agree
26	2. Agree
27	3. Disagree
28	4. Strongly disagree
29	5. Can't say
30	Comments/suggestions:
31	
32	If you strongly agree or agree with the statement, how would you stratify the importance of the
33	predictor within the context of risk stratification and surveillance strategies?
34	1. High importance
35	2. Medium importance
36	3. Low importance
37	
38	Is “ <i>unplanned adjunctive procedure other than in the proximal neck</i> ” an important predictor of
39	adverse events after EVAR that should be considered in risk stratification and surveillance
40	strategies?
41	1. Strongly agree
42	2. Agree
43	3. Disagree
44	4. Strongly disagree
45	5. Can't say
46	Comments/suggestions:
47	
48	If you strongly agree or agree with the statement, how would you stratify the importance of the
49	predictor within the context of risk stratification and surveillance strategies?
50	1. High importance
51	2. Medium importance
52	3. Low importance
53	
54	Would you suggest any other procedure performance-related predictors of adverse outcomes
55	after EVAR?
56	
57	Domain 4 - Postoperative surveillance imaging
58	Is “ <i>non-satisfactory seal at landing/overlapping zones</i> ” an important predictor of adverse events
59	after EVAR that should be considered in risk stratification and surveillance strategies?
60	1. Strongly agree

1	2. Agree
2	3. Disagree
3	4. Strongly disagree
4	5. Can't say
5	Comments/suggestions:
6	If you strongly agree or agree with the statement, how would you stratify the importance of the
7	predictor within the context of risk stratification and surveillance strategies?
8	1. High importance
9	2. Medium importance
10	3. Low importance
11	Is "endoleak (type II)" an important predictor of adverse events after EVAR that should be
12	considered in risk stratification and surveillance strategies?
13	1. Strongly agree
14	2. Agree
15	3. Disagree
16	4. Strongly disagree
17	5. Can't say
18	Comments/suggestions:
19	If you strongly agree or agree with the statement, how would you stratify the importance of the
20	predictor within the context of risk stratification and surveillance strategies?
21	1. High importance
22	2. Medium importance
23	3. Low importance
24	Is "no sac shrinkage (stable or expanding aneurysm sac)" ^c an important predictor of adverse
25	events after EVAR that should be considered in risk stratification and surveillance strategies?
26	1. Strongly agree
27	2. Agree
28	3. Disagree
29	4. Strongly disagree
30	5. Can't say
31	Comments/suggestions:
32	If you strongly agree or agree with the statement, how would you stratify the importance of the
33	predictor within the context of risk stratification and surveillance strategies?
34	1. High importance
35	2. Medium importance
36	3. Low importance
37	Is "sac expansion" ^c an important predictor of adverse events after EVAR that should be considered
38	in risk stratification and surveillance strategies?
39	1. Strongly agree
40	2. Agree
41	3. Disagree
42	4. Strongly disagree
43	5. Can't say
44	Comments/suggestions:
45	If you strongly agree or agree with the statement, how would you stratify the importance of the
46	predictor within the context of risk stratification and surveillance strategies?
47	1. High importance
48	2. Medium importance
49	3. Low importance
50	Is "sac expansion" ^c an important predictor of adverse events after EVAR that should be considered
51	in risk stratification and surveillance strategies?
52	1. Strongly agree
53	2. Agree
54	3. Disagree
55	4. Strongly disagree
56	5. Can't say
57	Comments/suggestions:
58	If you strongly agree or agree with the statement, how would you stratify the importance of the
59	predictor within the context of risk stratification and surveillance strategies?
60	1. High importance
	2. Medium importance
	3. Low importance
	Would you suggest any other postoperative surveillance imaging-related predictors of adverse
	outcomes after EVAR?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^adefined as diameter >25 mm.

^bcalculated by dividing the distance along the central lumen line from the aortic bifurcation to the common femoral artery by the straight-line distance from the aortic bifurcation to the common femoral artery. A ratio of <1.25 is optimal while a ratio of >1.6 is deemed as severe.

^csac expansion or sac shrinkage is defined as a 5 cm increase or decrease in the size of the abdominal aortic aneurysm sac between two surveillance imaging tests of the same mode.

Appendix 1. Tier 1 survey: Defining prognostic factors of endovascular aneurysm repair that should be considered in risk stratification and surveillance strategies. AAA, abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; IFU, instructions for use; IMA, inferior mesenteric artery.

For peer review only

Domain 1 – Preoperative anatomy

In **domain 1**, if all factors are answered with “yes”, the risk for the domain will be low.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors of **high importance** are answered with “yes”, the risk for the domain will be low.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors of **high importance** are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if at least 1 factor is answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if at least 1 factor of **high importance** is answered with “no”, the risk for the domain will be high.

6. Strongly agree
7. Agree
8. Disagree
9. Strongly disagree
10. Can't say

Comments/suggestions:

In **domain 1**, if at least 2 factors are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree

1	4. Strongly disagree
2	5. Can't say
3	Comments/suggestions:
4	In domain 1 , if at least 2 factors of high importance are answered with "no", the risk for the
5	domain will be high.
6	1. Strongly agree
7	2. Agree
8	3. Disagree
9	4. Strongly disagree
10	5. Can't say
11	Comments/suggestions:
12	In domain 1 , if at least 3 factors are answered with "no", the risk for the domain will be high.
13	1. Strongly agree
14	2. Agree
15	3. Disagree
16	4. Strongly disagree
17	5. Can't say
18	Comments/suggestions:
19	In domain 1 , if at least 3 factors of high importance are answered with "no", the risk for the
20	domain will be high.
21	1. Strongly agree
22	2. Agree
23	3. Disagree
24	4. Strongly disagree
25	5. Can't say
26	Comments/suggestions:
27	In domain 1 , if at least 3 factors of high importance are answered with "no", the risk for the
28	domain will be high.
29	1. Strongly agree
30	2. Agree
31	3. Disagree
32	4. Strongly disagree
33	5. Can't say
34	Comments/suggestions:
35	Any other suggestions about stratifying risk in domain 1?
36	Domain 2 – Aortic device
37	In domain 2 , if all factors are answered with "yes", the risk for the domain will be low.
38	1. Strongly agree
39	2. Agree
40	3. Disagree
41	4. Strongly disagree
42	5. Can't say
43	Comments/suggestions:
44	In domain 2 , if all factors of high importance are answered with "yes", the risk for the domain will
45	be low.
46	1. Strongly agree
47	2. Agree
48	3. Disagree
49	4. Strongly disagree
50	5. Can't say
51	Comments/suggestions:
52	In domain 2 , if all factors are answered with "no", the risk for the domain will be high.
53	1. Strongly agree
54	2. Agree
55	3. Disagree
56	4. Strongly disagree
57	5. Don't know

1	Comments/suggestions:
2	
3	
4	In domain 2 , if all factors of high importance are answered with “no”, the risk for the domain will
5	be high.
6	1. Strongly agree
7	2. Agree
8	3. Disagree
9	4. Strongly disagree
10	5. Can’t say
11	Comments/suggestions:
12	
13	In domain 2 , if at least 1 factor is answered with “no”, the risk for the domain will be high.
14	1. Strongly agree
15	2. Agree
16	3. Disagree
17	4. Strongly disagree
18	5. Can’t say
19	Comments/suggestions:
20	
21	In domain 2 , if at least 1 factor of high importance is answered with “no”, the risk for the domain
22	will be high.
23	1. Strongly agree
24	2. Agree
25	3. Disagree
26	4. Strongly disagree
27	5. Can’t say
28	Comments/suggestions:
29	
30	Any other suggestions about stratifying risk in domain 2?
31	
32	
33	Domain 3 – Procedure performance
34	In domain 3 , if all factors are answered with “yes”, the risk for the domain will be low.
35	1. Strongly agree
36	2. Agree
37	3. Disagree
38	4. Strongly disagree
39	5. Can’t say
40	Comments/suggestions:
41	
42	In domain 3 , if all factors of high importance are answered with “yes”, the risk for the domain will
43	be low.
44	1. Strongly agree
45	2. Agree
46	3. Disagree
47	4. Strongly disagree
48	5. Can’t say
49	Comments/suggestions:
50	
51	In domain 3 , if all factors are answered with “no”, the risk for the domain will be high.
52	1. Strongly agree
53	2. Agree
54	3. Disagree
55	4. Strongly disagree
56	5. Can’t say
57	Comments/suggestions:
58	
59	In domain 3 , if all factors of high importance are answered with “no”, the risk for the domain will
60	be high.

1	1. Strongly agree
2	2. Agree
3	3. Disagree
4	4. Strongly disagree
5	5. Can't say
6	Comments/suggestions:
7	In domain 3 , if at least 1 factor is answered with "no", the risk for the domain will be high.
8	1. Strongly agree
9	2. Agree
10	3. Disagree
11	4. Strongly disagree
12	5. Can't say
13	Comments/suggestions:
14	In domain 3 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
15	1. Strongly agree
16	2. Agree
17	3. Disagree
18	4. Strongly disagree
19	5. Can't say
20	Comments/suggestions:
21	In domain 3 , if at least 2 factors are answered with "no", the risk for the domain will be high.
22	1. Strongly agree
23	2. Agree
24	3. Disagree
25	4. Strongly disagree
26	5. Can't say
27	Comments/suggestions:
28	In domain 3 , if at least 2 factors of high importance are answered with "no", the risk for the domain will be high.
29	1. Strongly agree
30	2. Agree
31	3. Disagree
32	4. Strongly disagree
33	5. Can't say
34	Comments/suggestions:
35	Any other suggestions about stratifying risk in domain 3?
36	Domain 4 – Postoperative surveillance
37	In domain 4 , if all factors are answered with "yes", the risk for the domain will be low.
38	1. Strongly agree
39	2. Agree
40	3. Disagree
41	4. Strongly disagree
42	5. Can't say
43	Comments/suggestions:
44	In domain 4 , if all factors of high importance are answered with "yes", the risk for the domain will be low.
45	1. Strongly agree
46	2. Agree
47	3. Disagree
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1	4. Strongly disagree
2	5. Can't say
3	Comments/suggestions:
4	In domain 4 , if all factors are answered with "no", the risk for the domain will be high.
5	1. Strongly agree
6	2. Agree
7	3. Disagree
8	4. Strongly disagree
9	5. Can't say
10	Comments/suggestions:
11	In domain 4 , if all factors of high importance are answered with "no", the risk for the domain will be high.
12	1. Strongly agree
13	2. Agree
14	3. Disagree
15	4. Strongly disagree
16	5. Can't say
17	Comments/suggestions:
18	In domain 4 , if at least 1 factor is answered with "no", the risk for the domain will be high.
19	1. Strongly agree
20	2. Agree
21	3. Disagree
22	4. Strongly disagree
23	5. Can't say
24	Comments/suggestions:
25	In domain 4 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
26	1. Strongly agree
27	2. Agree
28	3. Disagree
29	4. Strongly disagree
30	5. Can't say
31	Comments/suggestions:
32	In domain 4 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
33	1. Strongly agree
34	2. Agree
35	3. Disagree
36	4. Strongly disagree
37	5. Can't say
38	Comments/suggestions:
39	Any other suggestions about risk stratification in domain 4?
40	
41	Risk stratification
42	If the risk in all domains is low, the overall risk should be low.
43	1. Strongly agree
44	2. Agree
45	3. Disagree
46	4. Strongly disagree
47	5. Can't say
48	Comments/suggestions:
49	If the risk in all domains is high, the overall risk should be high.
50	1. Strongly agree
51	2. Agree
52	3. Disagree
53	4. Strongly disagree
54	5. Can't say
55	Comments/suggestions:
56	If the risk in at least 1 domain is high, the overall risk should be low.
57	
58	
59	
60	

1.	Strongly agree
2.	Agree
3.	Disagree
4.	Strongly disagree
5.	Can't say
Comments/suggestions:	
Any other suggestions about the overall risk stratification?	

Appendix 2. Tier 2 survey: Defining the risk stratification model.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surveillance strategies should be risk specific, e.g. patients that have been judged to be high risk for developing adverse events after EVAR should have different surveillance than low risk patients.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Low risk

For **low risk** patients, surveillance should be with US and X-ray annually, with a CT angiogram at 5 years, unless there is sac expansion and/or migration, when CT should be performed.

6. Strongly agree
7. Agree
8. Disagree
9. Strongly disagree
10. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US and X-ray annually, with a CT angiogram only if there is sac expansion and/or migration.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US annually, with a CT angiogram only if there is sac expansion.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Low risk patients should have no surveillance at all.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Any other suggestions about surveillance strategies in low risk patients?

1	
2	
3	
4	Intermediate risk
5	Intermediate risk patients should have the same surveillance as low risk patients.
6	1. Strongly agree
7	2. Agree
8	3. Disagree
9	4. Strongly disagree
10	5. Can't say
11	Comments/suggestions:
12	Intermediate risk patients should have the same surveillance as high risk patients.
13	1. Strongly agree
14	2. Agree
15	3. Disagree
16	4. Strongly disagree
17	5. Can't say
18	Comments/suggestions:
19	Any other suggestions about surveillance strategies in intermediate risk patients?
20	
21	
22	
23	High risk
24	For high risk patients, surveillance should be with annual CT angiogram.
25	1. Strongly agree
26	2. Agree
27	3. Disagree
28	4. Strongly disagree
29	5. Can't say
30	Comments/suggestions:
31	For high risk patients, surveillance should be with annual CT angiogram and US+X-ray alternately (one year CT, next year US+X-ray).
32	1. Strongly agree
33	2. Agree
34	3. Disagree
35	4. Strongly disagree
36	5. Can't say
37	Comments/suggestions:
38	For high risk patients, surveillance should be with annual CT angiogram and US alternately (one year CT, next year US).
39	1. Strongly agree
40	2. Agree
41	3. Disagree
42	4. Strongly disagree
43	5. Can't say
44	Comments/suggestions:
45	For high risk patients, surveillance should be with US and X-ray annually, with a CT angiogram at 5 years, unless there is sac expansion and/or migration, when CT should be performed.
46	1. Strongly agree
47	2. Agree
48	3. Disagree
49	4. Strongly disagree
50	5. Can't say
51	Comments/suggestions:
52	For high risk patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.
53	1. Strongly agree
54	2. Agree
55	3. Disagree
56	4. Strongly disagree
57	5. Can't say
58	Comments/suggestions:
59	For high risk patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.
60	

1	
2	
3	
4	1. Strongly agree
5	2. Agree
6	3. Disagree
7	4. Strongly disagree
8	5. Can't say
9	Comments/suggestions:
10	For high risk patients, surveillance should be with US and X-ray annually, with a CT angiogram only
11	if there is sac expansion and/or migration.
12	1. Strongly agree
13	2. Agree
14	3. Disagree
15	4. Strongly disagree
16	5. Can't say
17	Comments/suggestions:
18	For high risk patients, surveillance should be with US annually, with a CT angiogram only if there
19	is sac expansion.
20	1. Strongly agree
21	2. Agree
22	3. Disagree
23	4. Strongly disagree
24	5. Can't say
25	Comments/suggestions:
26	Any other suggestions about surveillance strategies in high risk patients?
27	
28	What do you think the role of contrast-enhanced US in EVAR surveillance should be (choose one
29	or more)?
30	1. It should always be used instead of standard US.
31	2. It should always be used instead of CT.
32	3. It should be used instead of CT in cases where contraindications to CT exist.
33	4. It should be used only in cases of uncertainty as to the origin of endoleak.
34	5. There is no role.
35	6. Other (please, specify).
36	Comments/suggestions:
37	What do you think the role of DSA in EVAR surveillance should be?
38	1. It should be used in cases of indeterminate endoleak.
39	2. There is no role.
40	3. Other (please, specify)
41	Comments/suggestions:
42	What do you think the threshold for sac expansion that should trigger further
43	investigations/interventions should be?
44	1. 5 mm
45	2. 10 mm
46	3. 15 mm
47	4. There should be no threshold; any sac expansion should be acted upon.
48	5. Other (please, specify)
49	Comments/suggestions:
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What do you think the threshold for graft migration that should trigger further investigations/interventions should be?

1. 5 mm
2. 10 mm
3. 15 mm
4. There should be no threshold; any graft migration should be acted upon.
5. Other (please, specify)

Comments/suggestions:

Appendix 3. Tier 3 survey: Defining endovascular aneurysm repair surveillance strategies. CT, computed tomography; DSA, digital subtraction angiography; EVAR, endovascular aneurysm repair; US, ultrasonography.

For peer review only

BMJ Open

Risk factors, risk stratification and risk-specific surveillance strategies after endovascular aneurysm repair: Study protocol for a Delphi study by the International Risk Stratification in EVAR (IRIS- EVAR) working group

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055803.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Nov-2021
Complete List of Authors:	Antoniou, George A.; Royal Oldham Hospital, Department of Vascular & Endovascular Surgery Schermerhorn , Marc L. ; Beth Israel Deaconess Medical Center and Harvard Medical School Forbes, Thomas; Peter Munk Cardiac Centre, Division of Vascular Surgery Cheng, Vincent; University of Bristol , Bristol Medical School Antoniou, Stavros; Mediterranean Hospital of Cyprus, Golledge, Jonathan; James Cook University Queensland Research Centre for Peripheral Vascular Disease, Vascular Biology Unit; Townsville Hospital and Health Service, Department of Vascular and Endovascular Surgery, The Townsville Hospital, Queensland, Australia Verhagen, H; Erasmus Universiteit Rotterdam, Torella, Francesco; Liverpool University Hospitals NHS Foundation Trust, Liverpool vascular & Endovascular Service; University of Liverpool, School of Physical Sciences
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Diagnostics, Evidence based practice
Keywords:	VASCULAR SURGERY, Adult surgery < SURGERY, ULTRASONOGRAPHY, Computed tomography < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

1
2
3 **Risk factors, risk stratification and risk-specific surveillance strategies after endovascular aneurysm**
4 **repair: Study protocol for a Delphi study by the International Risk Stratification in EVAR (IRIS-**
5 **EVAR) working group**
6
7
8
9
10
11
12
13

14 ^{1,2}George A. Antoniou MD, PhD, MSc, FEBVS

17 ³Marc L. Schermerhorn MD

20 ⁴Thomas L. Forbes MD

23 ⁵Vincent Cheng BSc, MSc, PGDiP, DPhil

26 ^{6,7}Stavros A. Antoniou MD, PhD, MPH, FEBS, FACS

29 ^{8,9,10}Jonathan Golledge MB BChir, MA, FRCS, FRACS, MChir

32 ¹¹Hence J.M. Verhagen MD, PhD

35 ^{12,13,14}Francesco Torella MD, FRCS

38
39
40
41
42
43 ¹Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute
44 Hospitals NHS Trust, Northern Care Alliance NHS Group, Manchester, United Kingdom

47
48
49 ²Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester,
50 Manchester, United Kingdom

51
52
53
54 ³Divisions of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston,
55 Mass, United States of America
56
57
58
59
60

1
2
3 ⁴Division of Vascular Surgery, Peter Munk Cardiac Centre and University Health Network, University
4
5 of Toronto, Toronto, Ontario, Canada
6
7

8 ⁵Bristol Medical School, University of Bristol, Bristol, United Kingdom
9
10

11 ⁶Medical School, European University of Cyprus, Nicosia, Cyprus
12
13

14 ⁷Department of Surgery, Mediterranean Hospital of Cyprus, Limassol, Cyprus
15
16

17 ⁸Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry,
18
19 James Cook University, Townsville, Australia
20
21

22 ⁹Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville,
23
24 Australia
25
26

27 ¹⁰Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia
28
29

30 ¹¹Division of Vascular and Endovascular Surgery, Erasmus University Medical Centre, Rotterdam, The
31
32 Netherlands.
33
34

35 ¹²Liverpool Vascular & Endovascular Service, Liverpool, United Kingdom
36
37

38 ¹³School of Physical Sciences, University of Liverpool, Liverpool, United Kingdom
39
40

41 ¹⁴Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
42
43
44
45
46
47
48
49
50

51 **Corresponding author:** Professor Francesco Torella
52

53
54 Address: Liverpool University Hospitals NHS Foundation Trust, Liverpool Vascular & Endovascular
55
56 Service, Prescot Street, Liverpool, UK L7 8XP. Email: f.torella@liv.ac.uk
57
58

59 **ABSTRACT**
60

1
2
3 **Introduction:** Several risk factors for adverse events after endovascular aneurysm repair (EVAR) have
4 been described, but there is no consensus on their comparative prognostic significance, use in risk
5 stratification and application in determining postoperative surveillance.
6
7
8

9
10
11 **Methods and analysis:** A scoping review of the literature was conducted to identify risk factors for
12 adverse events after EVAR. Main adverse events were considered post-EVAR abdominal aortic
13 aneurysm rupture and reintervention. Risk factors were grouped into four domains: 1) preoperative
14 anatomy, 2) aortic device, 3) procedure performance, and 4) postoperative surveillance. The Delphi
15 methodology will be used to steer a group of experts in the field towards consensus organised into
16 three tiers. In tier 1, participants will be asked to independently rate risk factors for adverse events
17 after EVAR. In tier 2, the panel will be asked to independently rate a range of combinations of risk
18 factors across the four domains derived from tier 1. A risk-stratification tool will then be built, which
19 will include algorithms that map responses to signalling questions onto a proposed risk judgement
20 for each domain. Domain-level judgements will in turn provide the basis for an overall risk
21 judgement for the individual patient. In tier 3, risk factor-informed surveillance strategies will be
22 developed. Each tier will typically include three rounds and rating will be conducted using a four-
23 point Likert scale, with an option for free text responses.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Ethics and dissemination:** Research Ethics Committee and Health Research Authority approval has
42 been waived, since this is a professional staff study and no duty of care lies with the NHS to any of
43 the participants. The results will be presented at regional, national and international meetings, and
44 will be submitted for publication in peer-reviewed journals. The risk stratification tool and
45 surveillance algorithms will be made publicly available for clinical use and validation.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- 1
2
3 1. This is the first study to apply a structured, systematic, interactive, forecasting Delphi
4 methodology to steer a multidisciplinary group of experts in the field of endovascular
5 aneurysm repair (EVAR) towards consensus.
6
7
8
- 9
10
11 2. This study aims to identify the most important and clinically relevant risk factors for adverse
12 events (i.e. abdominal aortic aneurysm rupture and reintervention) after EVAR, develop risk
13 stratification models, and propose risk factor-specific surveillance strategies.
14
15
16
- 17
18 3. This study has the potential to provide an evidence and expert opinion informed risk
19 stratification tool for use in clinical practice.
20
21
22
- 23
24 4. Risk stratification and risk-informed surveillance strategies will be based on consensus
25 among experts rather than higher levels of evidence; this is an inherent weakness of the
26 study
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Abdominal aortic aneurysm (AAA) is an important cause of death in older adults. The only established treatments for AAA are endovascular aneurysm repair (EVAR) or open surgical repair. EVAR is a less invasive treatment with lower perioperative mortality, shorter hospital stay and quicker recovery than open surgical repair. EVAR, however, has inferior long-term outcomes than open surgical repair, including increased risk of aneurysm rupture, secondary intervention and aneurysm-related mortality.¹⁻³ In order to select the most appropriate AAA treatment, clinicians need to consider AAA rupture risk, perioperative risk and durability of treatment.

Several risk factors for adverse events following EVAR, including post-EVAR AAA rupture and reintervention, have been identified, such as hostile aortic anatomy and postoperative AAA growth.^{4,5} Risk factors have the potential to inform decision making and tailor management to individual patients, optimise perioperative care and customise surveillance, with a view to mitigating the risk of complications. Prior research has been conducted in developing risk stratification tools in the setting of standard EVAR, which has mostly considered preoperative clinical and morphological factors.⁶⁻⁹ Such risk models have had little impact and utility in clinical practice and many are obsolete, since they were developed based on old generation aortic devices, practices and technologies. Prior research suggests that risk factors for complications after EVAR can be grouped into four domains: 1) preoperative anatomy, 2) aortic device, 3) procedure performance, and 4) postoperative surveillance.¹⁰ No previous research has investigated the significance of parameters from across all four domains in risk prediction modelling and stratification. Furthermore, no previous studies have developed an expert consensus informed risk stratification incorporating a combination of such factors.

1
2
3 It is unlikely that risk stratification systems including all variables from the aforementioned
4 domains will be developed within randomized clinical trials, because of logistical difficulties with
5 recruiting large numbers of patients and long-term follow-up.¹¹ Similar difficulties may be
6 encountered with well designed and executed prospective cohort and registry studies, which would
7 need a long follow-up to provide robust knowledge on surveillance strategies in EVAR, that may be
8 of little use in light of the constantly evolving endovascular practices and technologies. Given the
9 current uncertainty surrounding risk stratification and the variability in follow-up routines in EVAR, a
10 structured, systematic, interactive, forecasting Delphi approach using expert opinions may enable
11 the development of an appropriate tool that can inform clinical practice.
12
13
14
15
16
17
18
19
20
21
22
23

24 In this study, the Delphi methodology will be used to develop a consensus of expert
25 opinions. The objective is to identify the most important and clinically relevant risk factors for
26 adverse events (i.e. abdominal aortic aneurysm rupture and reintervention) after EVAR, develop risk
27 stratification models, and propose risk factor-specific surveillance strategies.
28
29
30
31
32
33

34 **METHODS**

35 **Setting the forecasting task**

36
37
38 A scoping literature review was conducted on PubMed/MEDLINE from inception of EVAR to the
39 present date to identify prognostic studies investigating the prognostic value of anatomical,
40 procedural and surveillance parameters in standard EVAR. The focus of the literature search was to
41 identify risk factors which may usefully inform surveillance strategies to mitigate the risk of adverse
42 clinical outcomes, such as post-EVAR AAA rupture and secondary intervention. Two authors
43 screened reports and confirmed eligibility of studies. Preoperative, intraoperative, procedural and
44 postoperative imaging risk factors predictive of outcome after standard EVAR were listed and
45 defined. Such parameters were summarized in a table and a qualitative analysis was undertaken
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (Table 1). The published evidence has been previously assessed using the GRADE (Grading of
4
5 Recommendations, Assessment, Development and Evaluation) framework.^{5,12,13}
6
7

8
9 In light of the low quality evidence on and lack of clarity over the comparative prognostic
10
11 significance of prognostic factors, their use in risk stratification and their impact on modes and
12
13 strategies of follow-up in the setting of EVAR,¹⁴ the Delphi methodology will be used to steer a group
14
15 of experts in the field towards consensus.¹⁵
16
17

18 **Steering committee, facilitators and expert panel**

19
20
21 The Delphi task will be conducted by the following three distinct groups:
22
23

- 24
25 1. Steering committee
- 26
27 2. Facilitators
- 28
29 3. Expert Delphi committee
- 30
31
32
33

34
35 The role of the steering committee will be to analyse and appraise the available evidence,
36
37 design the Delphi study, analyse the Delphi participant responses, agree on risk stratification
38
39 system(s) and surveillance strategies (that will be developed based on consensus from the expert
40
41 Delphi committee), and propose areas for future research. The steering committee are an
42
43 interdisciplinary group consisting of vascular surgeons and endovascular specialists, and experts in
44
45 outreach, knowledge and evidence search and synthesis.
46
47
48

49
50 The facilitators are two members of the steering committee who will supervise the process
51
52 and communicate between the steering committee and the Delphi panel. They will be responsible
53
54 for the design and administration of the iterative Delphi process. The facilitators will formulate the
55
56 survey questions, disseminate the questions via the Delphi platform, facilitate the responses of and
57
58 provide feedback to the panel experts, and generate the final forecasts.
59
60

1
2
3 The composition and size of the expert Delphi panel will be decided by the steering
4 committee. Delphi panellists will be selected based on specialist knowledge, qualifications and a
5 proven track record in the field. The steering committee will focus on inviting experts with a varied
6 clinical and research background, with the intent to include, in particular, individuals with substantial
7 knowledge of the bio-mechanics of the stented aorta. Expertise will be defined by relevant
8 publications, successful relevant research grant applications or membership in relevant guideline
9 committees. Clinical and policy development experience will also be considered. International
10 experts will be included to account for variability in clinical practices and ensure group dynamics in
11 reaching consensus. A varied panel will be selected ensuring geographical, sex and age diversity.¹⁶
12
13 Vascular surgeons, interventional radiologists, other clinicians dealing with vascular disease (e.g.
14 angiologists and interventional cardiologists), EVAR surveillance coordinators and vascular nurse
15 specialists will be considered. Fifty experts will be invited via e-mail to participate in the Delphi
16 panel. A reminder will be sent via e-mail a week after the first invite, in case of no response. A
17 minimum of 35 Delphi members will be required to reach consensus.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Delphi panellists will be fluent in English and be affiliated with an academic or health service
36 institution. All experts will have an equal contribution, i.e. equal voting. To complete the Delphi
37 process, participants will be required to respond across all rounds. Those who do not respond in the
38 first round will not be invited to participate in subsequent rounds. Baseline demographics (age,
39 gender), country of residence, current role (consultant, trainee doctor, other health professional),
40 academic degree(s) and duration of experience in the field will be recorded at the start of the
41 survey.
42
43
44
45
46
47
48
49
50
51

52 Anticipated difficulties with continued commitment and engagement of Delphi members in
53 the process will be addressed by careful selection of national and international experts with a
54 demonstrated interest in the field. Our objective is to build a coherent team working collaboratively
55
56
57
58
59
60

1
2
3 towards consensus within the iterative Delphi process. Collaborative group authorship will be
4
5 offered to incentivise participating members.
6
7

8 **Questionnaires/surveys**

9
10
11 The entire project will comprise of three tiers (Figure 1). Each tier will constitute a distinct Delphi
12
13 process, which is aimed to include three rounds, unless consensus is achieved earlier in the
14
15 process.¹⁷ Attempts will be made to have the same Delphi panel in all three tiers, but the
16
17 composition of the panel is expected to vary between the tiers, depending on the availability and
18
19 willingness of Delphi experts to participate in all three Delphi processes. Examples of planned Delphi
20
21 surveys are presented in Appendix 1-3.
22
23
24

25 **Tier 1**

26
27 In tier 1, participants will be asked to independently rate individual proposed risk factors for adverse
28
29 events after standard EVAR with infra-renal devices across four distinct domains: 1) preoperative
30
31 anatomical factors, 2) aortic device-related factors, 3) intraoperative/procedure-related factors, and
32
33 4) postoperative surveillance imaging factors (Table 1, Appendix 1). The adverse events of interest
34
35 are post-EVAR AAA rupture and reintervention. The risk factors have been identified during the
36
37 literature search. Risk factors that are deemed the most consistently identified will be selected by
38
39 the steering committee. The focus of the expert Delphi panel will be directed towards the
40
41 importance of including such factors in risk stratification following EVAR with a view to developing
42
43 risk-specific surveillance algorithms.
44
45
46
47
48
49

50
51 The rating will be conducted using a four-point Likert scale, i.e. “strongly agree”, “agree”,
52
53 “disagree” and “strongly disagree”.¹⁸ For each item, participants will be given the option to select
54
55 “can’t say” as an alternative response to reflect neutrality. A free-text response within each domain
56
57 will be available to participants, providing the opportunity to suggest additional risk factors and
58
59 elaborate on their responses. Additional risk factors suggested by Delphi panel members will be
60

1
2
3 considered by the steering committee for inclusion in the subsequent Delphi rounds. If responders
4
5 “strongly agree” or “agree” with a specific risk factor being an important predictor of adverse events
6
7 after EVAR, it will be considered in risk stratification and surveillance strategies. The participant will
8
9 then be asked to stratify the importance of this factor in surveillance tailoring by choosing one of the
10
11 following options: “high importance”, “medium importance” or “low importance”. The Delphi round
12
13 will be repeated until consensus is reached. Feedback to the experts will include summary statistics
14
15 and outlines of qualitative justifications.
16
17

18 19 20 **Tier 2**

21
22
23 In tier 2, the Delphi panel will be asked to independently rate a range of combinations of risk factors
24
25 across the four domains. The risk factors will be those that were agreed upon in tier 1. The
26
27 importance of individual risk factors, as agreed upon in tier 1, will be considered in stratifying the
28
29 risk in individual domains. Based on the chosen risk factor combination, the risk for the specific
30
31 domain will be stratified as low or high. Then, consensus will be sought on stratifying the overall risk
32
33 as “low”, “intermediate” or “high” based on combinations of domain-specific risks (Appendix 2). The
34
35 questionnaire will be supplemented by a graphical summary of risk stratification models, which will
36
37 provide the Delphi participants with a list of risk factors, their importance and all possible
38
39 combinations to stratify domain-specific and overall risks (Figure 2).
40
41
42
43

44
45 The same methodology as that applied in tier 1 will be used, i.e. a four-point Likert scale,
46
47 “can’t say” option and free text response. Suggestions made by Delphi panel members about
48
49 stratifying risk in specific domains will be considered for inclusion in subsequent Delphi rounds. The
50
51 Delphi process will be repeated until consensus is reached. Feedback will also comprise graphical
52
53 presentations of findings.
54
55

56 57 58 **Tier 3**

1
2
3 The aim of tier 3 will be to develop risk-specific surveillance strategies. The survey will consist of a
4 combination of open-ended and close-ended questions concerning EVAR surveillance (Appendix 3).

5
6
7 Consensus will be sought on the following:

- 8
9
10
11 1. Whether the same surveillance strategy should be applied in low, intermediate and high-risk
12 patient groups (as defined in tier 2) or a specific surveillance strategy for low risk patients
13 and another strategy for intermediate and high-risk patients is needed.
14
15
16
17
18 2. Surveillance imaging modes (ultrasonography, computed tomography, plain X-ray or a
19 combination) and intervals (or time points) when surveillance imaging should be
20 undertaken.
21
22
23
24
25

26 Specific questions will be asked on the role of contrast enhanced ultrasonography and digital
27 subtraction angiography in EVAR surveillance. Furthermore, consensus will be sought on the
28 threshold of sac expansion and graft migration that should trigger further investigations and/or
29 interventions. Answers to such open-ended questions will be analysed applying descriptive statistics
30 to reach consensus (Appendix 3).
31
32
33
34
35
36
37

38 Expert participants will be asked to judge questions using the methodology presented in tier
39 1 and 2. Similar to Tier 1 and 2, suggestions made by Delphi panellists about surveillance strategies
40 for specific risk categories will be considered for inclusion in subsequent Delphi rounds. Delphi
41 rounds will be repeated until consensus is achieved. Feedback to the expert Delphi panel will include
42 a statistical summary, a summary of qualitative responses and graphical presentations of
43 surveillance algorithms.
44
45
46
47
48
49
50
51

52 **Risk stratification tool**

53
54
55
56 The risk stratification tool will be based on identified and agreed risk factors, will provide a
57 framework for considering the risk of adverse events, e.g. AAA rupture or reintervention, after
58
59
60

1
2
3 standard EVAR, and will guide tailored (or risk-specific) surveillance algorithms. The tool will be
4
5 structured into four domains, each consisting of distinct risk factors, and will be based on consensus
6
7 achieved in tier 1 and 2:
8
9

- 10 1. Preoperative anatomy
- 11
- 12
- 13
- 14 2. Aortic device
- 15
- 16
- 17 3. Procedure performance
- 18
- 19
- 20
- 21 4. Early surveillance
- 22

23
24 Signalling questions for individual risk factors within each domain will be answered with the
25
26 response options “yes” or “no”. An example of a signalling question is: “*Is the length of the proximal*
27
28 *aortic neck >15 mm?*”. The tool will provide space for free text alongside the signalling question, e.g.
29
30 for the clinician to provide a specific numerical value for the length of the proximal aortic neck.
31
32

33
34 The risk stratification tool will be conceived hierarchically: responses to signalling questions
35
36 will provide the basis for domain-level judgements about the risk of adverse events following EVAR
37
38 (low risk or high risk). In turn, these domain-level judgements will provide the basis for an overall risk
39
40 judgement for the individual patient being assessed. The tool will include algorithms that map
41
42 responses to signalling questions onto a proposed risk judgement for each domain. The possible risk
43
44 judgements are:
45
46

- 47
- 48 1. Low risk
- 49
- 50
- 51 2. Intermediate risk
- 52
- 53
- 54 3. High risk
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 The algorithms will provide proposed judgements, but users will be able to verify these and change
4 them if they feel this is appropriate. An online tool (web application) for clinical guide and validation
5 is planned.
6
7
8
9

10 **Data analysis**

11
12
13
14 The Bristol Online Surveys tool, which is an online tool designed for academic research, educational
15 and public sector organisations, will be used for the Delphi survey platform.¹⁹ Descriptive statistics
16 will be applied to describe characteristics of the Delphi panel participants and group responses to
17 each statement in all three rounds. Cronbach's alpha will be used to determine the internal
18 consistency of the assessment tool after each round. Consensus will be defined as >70% of
19 participants agreeing/strongly agreeing or disagreeing/strongly disagreeing with a statement in each
20 round.²⁰ "Can't say" responses will be excluded from the analyses to ensure that only responses
21 from experts who felt confident about their response are taken into account. If consensus is not
22 reached on one or more of the survey items at the end of each Delphi process, the steering
23 committee will consider the Delphi expert responses and decide on the most appropriate or popular
24 answers to the survey questions. An explicit statement that no consensus has been reached will be
25 added to the risk stratification tools/surveillance algorithms. Analyses will be conducted using SPSS
26 for windows.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Patient and public involvement**

45
46
47 The opinions of two patient advocates with personal experience in abdominal aortic aneurysm
48 treatment on surveillance algorithms proposed by the expert Delphi panel will be considered in Tier
49 3. Patient advocates are expected to provide their perspectives on feasibility and ease of
50 surveillance modes and strategies, patient experience, and potential impact on quality of life, and
51 make suggestions for optimisation of such practices. Such opinions will be reviewed by the steering
52 committee and presented in the final document.
53
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

This study will develop a risk stratification instrument, which will help vascular specialists better select the optimal treatment for AAA and tailor post-EVAR surveillance to the individual patient needs (personalised medicine), with the potential of reducing EVAR-related reinterventions, complications, and mortality. We plan to conduct further research aiming to externally validate the ability of the risk stratification tool, that will be developed from the present study, to predict adverse events (reintervention, AAA rupture, and death) after EVAR in a large population with AAA that have been treated in large tertiary NHS institutions. We believe that our study will pave the way for the development, validation, and application of the risk stratification tool that will be available for use by specialists in the treatment of AAA. Risk stratification will result in individualized (personalised) treatment and follow-up (surveillance) with a direct benefit for patients treated for AAA. Research Ethics Committee and Health Research Authority approval is waived, since this is a professional staff study and no duty of care lies with the NHS (National Health Service) to any of the participants. The study is anticipated to start as soon as the study protocol is published online in a peer-reviewed journal. The published study protocol will be sent to Delphi members along with the inviting letter. Electronic informed consent will be requested from Delphi participants at the start of round 1 of each Delphi process (tier). The Delphi processes for all three tiers are anticipated to be completed within 12 months from the date of the first invitation. The participating Delphi experts will remain anonymous during the entire process. The results of the study will be published (with the names of all participating Delphi members) after all three Delphi processes have been completed. All data will be handled in accordance with UK data protection regulations.

Information on conflict of interest will be obtained from steering committee members and Delphi panel participants. Potential conflicts of interest will be dealt with by re-assigning functions or replacing participants who pose interest conflict.

1
2
3 The results of the study will be presented at regional, national and international meetings.
4
5 The study findings will also be published in peer-reviewed journals. The Delphi panel's contribution
6
7 will be acknowledged by group authorship in peer-reviewed publications. Dissemination will also
8
9 occur through social media and other collaboration tools.
10
11
12

13 **Authors' contributions:**

14
15
16 George A. Antoniou: Conception, design, literature search and analysis, interpretation of data,
17
18 drafting the study protocol, approval.
19

20
21
22 Marc L. Schermerhorn: Design, interpretation of data, critical revision, approval.
23

24
25 Thomas L. Forbes: Design, interpretation of data, critical revision, approval.
26

27
28 Vincent Cheng: Design, critical revision, approval.
29

30
31 Stavros A. Antoniou: Conception, design, literature search and analysis, interpretation of data,
32
33 drafting the study protocol, critical revision, approval.
34

35
36
37 Jonathan Golledge: Design, interpretation of data, critical revision, approval.
38

39
40 Hence J.M. Verhagen: Design, interpretation of data, critical revision, approval.
41

42
43 Francesco Torella: Conception, design, literature analysis, interpretation of data, critical revision,
44
45 approval.
46
47

48
49
50
51
52 **Funding statement:** No funding has been obtained for this work.
53
54
55
56
57
58
59
60

1
2
3 **Competing interests statement:** Hence J.M. Verhagen has conflicts of interest with Medtronic, WL
4
5 Gore, Abbott, Endologix and Arsenal AAA. The rest of the authors have no conflicts of interest to
6
7 declare.
8
9

10 11 12 13 14 **REFERENCES**

- 15
16
17 1. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM; EVAR trial investigators. Endovascular
18 versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK
19 endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. *Lancet*.
20 2016;388:2366-2374.
21
22
- 23
24
25 2. Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT Jr, Matsumura JS, Huo Z,
26 Johnson GR; OVER Veterans Affairs Cooperative Study Group. Open versus endovascular
27 repair of abdominal aortic aneurysm. *N Engl J Med*. 2019;380:2126-2135.
28
29
- 30
31
32 3. Antoniou GA, Antoniou SA, Torella F. Endovascular vs. open repair for abdominal aortic
33 aneurysm: Systematic review and meta-analysis of updated peri-operative and long term
34 rata of randomised controlled trials. *Eur J Vasc Endovasc Surg*. 2020;59:385-397.
35
36
- 37
38
39 4. Antoniou GA, Georgiadis GS, Antoniou SA, Kuhan G, Murray D. A meta-analysis of outcomes
40 of endovascular abdominal aortic aneurysm repair in patients with hostile and friendly neck
41 anatomy. *J Vasc Surg*. 2013;57:527-38.
42
43
- 44
45
46 5. Antoniou GA, Alfahad A, Antoniou SA, Torella F. Prognostic significance of aneurysm sac
47 shrinkage after endovascular aneurysm repair. *J Endovasc Ther*. 2020;27:857-868.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 6. Karthikesalingam A, Holt PJ, Vidal-Diez A, Choke EC, Patterson BO, Thompson LJ, Ghatwary T,
4
5 Bown MJ, Sayers RD, Thompson MM. Predicting aortic complications after endovascular
6
7 aneurysm repair. *Br J Surg*. 2013;100:1302-11.
8
9
- 10
11 7. Png CYM, Tadros RO, Beckerman WE, Han DK, Tardiff ML, Torres MR, Marin ML, Faries PL.
12
13 An anatomic risk model to screen post endovascular aneurysm repair patients for aneurysm
14
15 sac enlargement. *J Surg Res*. 2017;217:29-35.e1.
16
17
- 18
19 8. Barnes M, Boulton M, Maddern G, Fitridge R. A model to predict outcomes for endovascular
20
21 aneurysm repair using preoperative variables. *Eur J Vasc Endovasc Surg*. 2008;35(5):571-9.
22
23
- 24
25 9. Chaikof EL, Fillinger MF, Matsumura JS, Rutherford RB, White GH, Blankensteijn JD, Bernhard
26
27 VM, Harris PL, Kent KC, May J, Veith FJ, Zarins CK. Identifying and grading factors that modify
28
29 the outcome of endovascular aortic aneurysm repair. *J Vasc Surg*. 2002;35(5):1061-6.
30
31
- 32
33 10. Antoniou GA. Risk stratification and risk-specific surveillance for endovascular aneurysm
34
35 repair. *Eur J Vasc Endovasc Surg*. DOI:<https://doi.org/10.1016/j.ejvs.2020.08.049>.
36
37
- 38
39 11. Wanhainen A. Response to "Re 'European Society for Vascular Surgery (ESVS) 2019 Clinical
40
41 Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms'". *Eur J*
42
43 *Vasc Endovasc Surg*. 2020;60(6):951
44
- 45
46 12. Antoniou GA, Juszczak MT, Nasr H, Narlawar R, Antoniou SA, Matsagkas M, Donas KP, de
47
48 Vries JPM. Prognosis review and time-to-event data meta-analysis of endovascular aneurysm
49
50 repair outside versus within instructions for use of aortic endograft devices. *J Vasc Surg*.
51
52 2020;71:1415-1431.e15.
53
- 54
55 13. Antoniou GA, Alfahad A, Antoniou SA, Badri H. Prognostic significance of large diameter
56
57 proximal aortic neck in endovascular aneurysm repair. *Vasa*. 2020;49:215-224.
58
59
60

- 1
2
3 14. Patel SR, Allen C, Grima MJ, Brownrigg JRW, Patterson BO, Holt PJE, Thompson MM,
4
5 Karthikesalingam A. A systematic review of predictors of reintervention after EVAR:
6
7 Guidance for risk-stratified surveillance. *Vasc Endovascular Surg.* 2017;51:417-428.
8
9
- 10
11 15. Jones J and Hunter D. Consensus methods for medical and health services research. *BMJ.*
12
13 1995;311:376-80.
14
15
- 16 16. Yancik R and Maklan CW. The Delphi method as a research tool in gerontological curriculum
17
18 planning. *Gerontol Geriatr Educ.* Spring 1981;1:163-8.
19
20
- 21 17. Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel:
22
23 application of bootstrap data expansion. *BMC Med Res Methodol.* 2005;5:37.
24
25
- 26 18. Iqbal S, Pison-Young L. The Delphi method. *Psychologist.* 2009;22:598-600.
27
28
- 29 19. Bristol Online Surveys. <https://www.onlinesurveys.ac.uk/>.
30
31
- 32 20. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, Wales PW. Defining
33
34 consensus: a systematic review recommends methodologic criteria for reporting of Delphi
35
36 studies. *J Clin Epidemiol.* 2014;67:401-9.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<p>Preoperative anatomy</p> <ul style="list-style-type: none"> • proximal aortic neck length >15 mm • proximal aortic neck diameter <30 mm • infra-renal angulation <60 degrees • supra-renal angulation <45 degrees • <50% circumferential proximal neck calcification • <50% circumferential proximal neck thrombus • non-conical proximal aortic neck • maximal AAA diameter <70 mm • ≤2 patent lumbar arteries plus non-patent IMA or ≤1 patent lumbar artery plus patent IMA • distal aortic neck diameter >18 mm • no common iliac artery aneurysm^a • distal iliac landing zone diameter <20 mm • distal iliac landing zone length >10 mm • iliac tortuosity index <1.25^b
<p>Aortic device</p> <ul style="list-style-type: none"> • anatomy complaint with IFU • supra-renal fixation device • infra-renal fixation device • EVAR procedure performed according to IFU
<p>Procedure performance</p> <ul style="list-style-type: none"> • good position of endografts in relation to distal, overlapping, and proximal landing zones • no non-type II endoleak/kink/stenosis on completion angiogram • no unplanned adjunctive procedures in the proximal neck • no unplanned adjunctive procedure other than in the proximal neck
<p>Postoperative surveillance</p> <ul style="list-style-type: none"> • satisfactory seal at landing/overlapping zones • no endoleak (type II) • sac shrinkage^c • no sac expansion^c

^adefined as diameter >25 mm

^bcalculated by dividing the distance along the central lumen line from the aortic bifurcation to the common femoral artery by the straight-line distance from the aortic bifurcation to the common femoral artery. A ratio of < 1.25 is optimal while a ratio of > 1.6 is deemed as severe.

^csac expansion or sac shrinkage is defined as a 5 mm increase or decrease in the size of the abdominal aortic aneurysm sac between two surveillance imaging tests of the same mode occurring during any time period.

Table 1. Prognostic factors of endovascular aneurysm repair that should be considered in risk stratification and surveillance strategies. AAA, abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; IFU, instructions for use; IMA, inferior mesenteric artery.


1
2
3 **Figure legends**
4

5
6 1 Structure of the study
7


8
9 2 Risk stratification model
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Structure of the study
178x139mm (72 x 72 DPI)



Risk stratification model

333x198mm (72 x 72 DPI)

Domain 1 – Preoperative anatomy

Is "*proximal aortic neck length <15 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*proximal aortic neck diameter >30 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*infra-renal neck angulation >60 degrees*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

1
2
3
4 Is "*supra-renal neck angulation >45 degrees*" an important predictor of adverse events after EVAR
5 that should be considered in risk stratification and surveillance strategies?

- 6 1. Strongly agree
7 2. Agree
8 3. Disagree
9 4. Strongly disagree
10 5. Can't say

11 Comments/suggestions:

12 If you strongly agree or agree with the statement, how would you stratify the importance of the
13 predictor within the context of risk stratification and surveillance strategies?

- 14 1. High importance
15 2. Medium importance
16 3. Low importance

17
18
19
20
21
22 Is "*>50% circumferential proximal aortic neck calcification*" an important predictor of adverse
23 events after EVAR that should be considered in risk stratification and surveillance strategies?

- 24 1. Strongly agree
25 2. Agree
26 3. Disagree
27 4. Strongly disagree
28 5. Can't say

29 Comments/suggestions:

30 If you strongly agree or agree with the statement, how would you stratify the importance of the
31 predictor within the context of risk stratification and surveillance strategies?

- 32 1. High importance
33 2. Medium importance
34 3. Low importance

35
36
37
38
39
40 Is "*>50% circumferential proximal aortic neck thrombus*" an important predictor of adverse events
41 after EVAR that should be considered in risk stratification and surveillance strategies?

- 42 1. Strongly agree
43 2. Agree
44 3. Disagree
45 4. Strongly disagree
46 5. Can't say

47 Comments/suggestions:

48 If you strongly agree or agree with the statement, how would you stratify the importance of the
49 predictor within the context of risk stratification and surveillance strategies?

- 50 1. High importance
51 2. Medium importance
52 3. Low importance
53
54
55
56
57
58
59
60

1
2
3
4 Is "*conical proximal aortic neck*" an important predictor of adverse events after EVAR that should
5 be considered in risk stratification and surveillance strategies?

- 6 1. Strongly agree
7 2. Agree
8 3. Disagree
9 4. Strongly disagree
10 5. Can't say

11 Comments/suggestions:

12 If you strongly agree or agree with the statement, how would you stratify the importance of the
13 predictor within the context of risk stratification and surveillance strategies?

- 14 1. High importance
15 2. Medium importance
16 3. Low importance

17
18
19
20
21
22 Is "*maximal AAA diameter >70 mm*" an important predictor of adverse events after EVAR that
23 should be considered in risk stratification and surveillance strategies?

- 24 1. Strongly agree
25 2. Agree
26 3. Disagree
27 4. Strongly disagree
28 5. Can't say

29 Comments/suggestions:

30 If you strongly agree or agree with the statement, how would you stratify the importance of the
31 predictor within the context of risk stratification and surveillance strategies?

- 32 1. High importance
33 2. Medium importance
34 3. Low importance

35
36
37
38
39
40 Is "*>2 patent lumbar arteries plus non-patent IMA or >1 patent lumbar artery plus patent IMA*" an
41 important predictor of adverse events after EVAR that should be considered in risk stratification
42 and surveillance strategies?

- 43 1. Strongly agree
44 2. Agree
45 3. Disagree
46 4. Strongly disagree
47 5. Can't say

48 Comments/suggestions:

49 If you strongly agree or agree with the statement, how would you stratify the importance of the
50 predictor within the context of risk stratification and surveillance strategies?

- 51 1. High importance
52 2. Medium importance
53 3. Low importance
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Is "*distal aortic neck diameter <18 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*common iliac artery aneurysm (if common iliac artery used as a landing zone)*"^a an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

Is "*distal iliac landing zone diameter >20 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?

1. High importance
2. Medium importance
3. Low importance

1
2
3
4 Is "*distal iliac landing zone length <10 mm*" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?

- 5
6 1. Strongly agree
7 2. Agree
8 3. Disagree
9 4. Strongly disagree
10 5. Can't say

11 Comments/suggestions:

12 If you strongly agree or agree with the statement, how would you stratify the importance of the
13 predictor within the context of risk stratification and surveillance strategies?

- 14 1. High importance
15 2. Medium importance
16 3. Low importance

17
18
19
20
21 Is "*iliac tortuosity index >1.25*"^b an important predictor of adverse events after EVAR that should
22 be considered in risk stratification and surveillance strategies?

- 23 1. Strongly agree
24 2. Agree
25 3. Disagree
26 4. Strongly disagree
27 5. Can't say

28 Comments/suggestions:

29
30 If you strongly agree or agree with the statement, how would you stratify the importance of the
31 predictor within the context of risk stratification and surveillance strategies?

- 32 1. High importance
33 2. Medium importance
34 3. Low importance

35
36
37
38
39 Would you suggest any other preoperative anatomy-related predictors of adverse outcomes after
40 EVAR?
41

42
43 **Domain 2 - Aortic device**

44 Is "*anatomy non-complaint with IFU*" an important predictor of adverse events after EVAR that
45 should be considered in risk stratification and surveillance strategies?

- 46 1. Strongly agree
47 2. Agree
48 3. Disagree
49 4. Strongly disagree
50 5. Can't say

51 Comments/suggestions:

52
53 If you strongly agree or agree with the statement, how would you stratify the importance of the
54 predictor within the context of risk stratification and surveillance strategies?

- 55 1. High importance
56 2. Medium importance
57 3. Low importance

58
59 Is "*supra-renal fixation device*" an important predictor of adverse events after EVAR that should
60 be considered in risk stratification and surveillance strategies?

<ol style="list-style-type: none"> 1. Strongly agree 2. Agree 3. Disagree 4. Strongly disagree 5. Can't say <p>Comments/suggestions:</p>
<p>If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. High importance 2. Medium importance 3. Low importance
<p>Is "<i>infra-renal fixation device</i>" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. Strongly agree 2. Agree 3. Disagree 4. Strongly disagree 5. Can't say <p>Comments/suggestions:</p>
<p>If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. High importance 2. Medium importance 3. Low importance
<p>Is "<i>EVAR procedure not performed according to IFU</i>" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. Strongly agree 2. Agree 3. Disagree 4. Strongly disagree 5. Can't say <p>Comments/suggestions:</p>
<p>If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. High importance 2. Medium importance 3. Low importance
<p>Would you suggest any other aortic device-related predictors of adverse outcomes after EVAR?</p>
<p>Domain 3 - Procedure performance</p>
<p>Is "<i>suboptimal position of endografts in relation to distal, overlapping, and proximal landing zones</i>" an important predictor of adverse events after EVAR that should be considered in risk stratification and surveillance strategies?</p> <ol style="list-style-type: none"> 1. Strongly agree 2. Agree 3. Disagree 4. Strongly disagree 5. Can't say <p>Comments/suggestions:</p>
<p>If you strongly agree or agree with the statement, how would you stratify the importance of the predictor within the context of risk stratification and surveillance strategies?</p>

1	
2	
3	
4	1. High importance
5	2. Medium importance
6	3. Low importance
7	Is “ <i>non-type II endoleak/kink/stenosis on completion angiogram</i> ” an important predictor of
8	adverse events after EVAR that should be considered in risk stratification and surveillance
9	strategies?
10	1. Strongly agree
11	2. Agree
12	3. Disagree
13	4. Strongly disagree
14	5. Can't say
15	Comments/suggestions:
16	
17	If you strongly agree or agree with the statement, how would you stratify the importance of the
18	predictor within the context of risk stratification and surveillance strategies?
19	1. High importance
20	2. Medium importance
21	3. Low importance
22	
23	Is “ <i>unplanned adjunctive procedures in the proximal neck</i> ” an important predictor of adverse
24	events after EVAR that should be considered in risk stratification and surveillance strategies?
25	1. Strongly agree
26	2. Agree
27	3. Disagree
28	4. Strongly disagree
29	5. Can't say
30	Comments/suggestions:
31	
32	If you strongly agree or agree with the statement, how would you stratify the importance of the
33	predictor within the context of risk stratification and surveillance strategies?
34	1. High importance
35	2. Medium importance
36	3. Low importance
37	
38	Is “ <i>unplanned adjunctive procedure other than in the proximal neck</i> ” an important predictor of
39	adverse events after EVAR that should be considered in risk stratification and surveillance
40	strategies?
41	1. Strongly agree
42	2. Agree
43	3. Disagree
44	4. Strongly disagree
45	5. Can't say
46	Comments/suggestions:
47	
48	If you strongly agree or agree with the statement, how would you stratify the importance of the
49	predictor within the context of risk stratification and surveillance strategies?
50	1. High importance
51	2. Medium importance
52	3. Low importance
53	Would you suggest any other procedure performance-related predictors of adverse outcomes
54	after EVAR?
55	
56	Domain 4 - Postoperative surveillance imaging
57	
58	Is “ <i>non-satisfactory seal at landing/overlapping zones</i> ” an important predictor of adverse events
59	after EVAR that should be considered in risk stratification and surveillance strategies?
60	1. Strongly agree

1	2. Agree
2	3. Disagree
3	4. Strongly disagree
4	5. Can't say
5	Comments/suggestions:
6	If you strongly agree or agree with the statement, how would you stratify the importance of the
7	predictor within the context of risk stratification and surveillance strategies?
8	1. High importance
9	2. Medium importance
10	3. Low importance
11	Is "endoleak (type II)" an important predictor of adverse events after EVAR that should be
12	considered in risk stratification and surveillance strategies?
13	1. Strongly agree
14	2. Agree
15	3. Disagree
16	4. Strongly disagree
17	5. Can't say
18	Comments/suggestions:
19	If you strongly agree or agree with the statement, how would you stratify the importance of the
20	predictor within the context of risk stratification and surveillance strategies?
21	1. High importance
22	2. Medium importance
23	3. Low importance
24	Is "no sac shrinkage (stable or expanding aneurysm sac)" ^c an important predictor of adverse
25	events after EVAR that should be considered in risk stratification and surveillance strategies?
26	1. Strongly agree
27	2. Agree
28	3. Disagree
29	4. Strongly disagree
30	5. Can't say
31	Comments/suggestions:
32	If you strongly agree or agree with the statement, how would you stratify the importance of the
33	predictor within the context of risk stratification and surveillance strategies?
34	1. High importance
35	2. Medium importance
36	3. Low importance
37	Is "sac expansion" ^c an important predictor of adverse events after EVAR that should be considered
38	in risk stratification and surveillance strategies?
39	1. Strongly agree
40	2. Agree
41	3. Disagree
42	4. Strongly disagree
43	5. Can't say
44	Comments/suggestions:
45	If you strongly agree or agree with the statement, how would you stratify the importance of the
46	predictor within the context of risk stratification and surveillance strategies?
47	1. High importance
48	2. Medium importance
49	3. Low importance
50	Is "sac expansion" ^c an important predictor of adverse events after EVAR that should be considered
51	in risk stratification and surveillance strategies?
52	1. Strongly agree
53	2. Agree
54	3. Disagree
55	4. Strongly disagree
56	5. Can't say
57	Comments/suggestions:
58	If you strongly agree or agree with the statement, how would you stratify the importance of the
59	predictor within the context of risk stratification and surveillance strategies?
60	1. High importance
	2. Medium importance
	3. Low importance
	Would you suggest any other postoperative surveillance imaging-related predictors of adverse
	outcomes after EVAR?

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^adefined as diameter >25 mm.

^bcalculated by dividing the distance along the central lumen line from the aortic bifurcation to the common femoral artery by the straight-line distance from the aortic bifurcation to the common femoral artery. A ratio of <1.25 is optimal while a ratio of >1.6 is deemed as severe.

^csac expansion or sac shrinkage is defined as a 5 cm increase or decrease in the size of the abdominal aortic aneurysm sac between two surveillance imaging tests of the same mode.

Appendix 1. Tier 1 survey: Defining prognostic factors of endovascular aneurysm repair that should be considered in risk stratification and surveillance strategies. AAA, abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; IFU, instructions for use; IMA, inferior mesenteric artery.

Domain 1 – Preoperative anatomy

In **domain 1**, if all factors are answered with “yes”, the risk for the domain will be low.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors of **high importance** are answered with “yes”, the risk for the domain will be low.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if all factors of **high importance** are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if at least 1 factor is answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

In **domain 1**, if at least 1 factor of **high importance** is answered with “no”, the risk for the domain will be high.

6. Strongly agree
7. Agree
8. Disagree
9. Strongly disagree
10. Can't say

Comments/suggestions:

In **domain 1**, if at least 2 factors are answered with “no”, the risk for the domain will be high.

1. Strongly agree
2. Agree
3. Disagree

1	
2	
3	
4	4. Strongly disagree
5	5. Can't say
6	Comments/suggestions:
7	In domain 1 , if at least 2 factors of high importance are answered with "no", the risk for the
8	domain will be high.
9	1. Strongly agree
10	2. Agree
11	3. Disagree
12	4. Strongly disagree
13	5. Can't say
14	Comments/suggestions:
15	In domain 1 , if at least 3 factors are answered with "no", the risk for the domain will be high.
16	1. Strongly agree
17	2. Agree
18	3. Disagree
19	4. Strongly disagree
20	5. Can't say
21	Comments/suggestions:
22	In domain 1 , if at least 3 factors of high importance are answered with "no", the risk for the
23	domain will be high.
24	1. Strongly agree
25	2. Agree
26	3. Disagree
27	4. Strongly disagree
28	5. Can't say
29	Comments/suggestions:
30	Any other suggestions about stratifying risk in domain 1?
31	
32	
33	
34	
35	
36	Domain 2 – Aortic device
37	In domain 2 , if all factors are answered with "yes", the risk for the domain will be low.
38	1. Strongly agree
39	2. Agree
40	3. Disagree
41	4. Strongly disagree
42	5. Can't say
43	Comments/suggestions:
44	In domain 2 , if all factors of high importance are answered with "yes", the risk for the domain will
45	be low.
46	1. Strongly agree
47	2. Agree
48	3. Disagree
49	4. Strongly disagree
50	5. Can't say
51	Comments/suggestions:
52	In domain 2 , if all factors are answered with "no", the risk for the domain will be high.
53	1. Strongly agree
54	2. Agree
55	3. Disagree
56	4. Strongly disagree
57	5. Don't know
58	
59	
60	

1	Comments/suggestions:
2	In domain 2 , if all factors of high importance are answered with “no”, the risk for the domain will
3	be high.
4	1. Strongly agree
5	2. Agree
6	3. Disagree
7	4. Strongly disagree
8	5. Can’t say
9	Comments/suggestions:
10	In domain 2 , if at least 1 factor is answered with “no”, the risk for the domain will be high.
11	1. Strongly agree
12	2. Agree
13	3. Disagree
14	4. Strongly disagree
15	5. Can’t say
16	Comments/suggestions:
17	In domain 2 , if at least 1 factor of high importance is answered with “no”, the risk for the domain
18	will be high.
19	1. Strongly agree
20	2. Agree
21	3. Disagree
22	4. Strongly disagree
23	5. Can’t say
24	Comments/suggestions:
25	Any other suggestions about stratifying risk in domain 2?
26	
27	Domain 3 – Procedure performance
28	In domain 3 , if all factors are answered with “yes”, the risk for the domain will be low.
29	1. Strongly agree
30	2. Agree
31	3. Disagree
32	4. Strongly disagree
33	5. Can’t say
34	Comments/suggestions:
35	In domain 3 , if all factors of high importance are answered with “yes”, the risk for the domain will
36	be low.
37	1. Strongly agree
38	2. Agree
39	3. Disagree
40	4. Strongly disagree
41	5. Can’t say
42	Comments/suggestions:
43	In domain 3 , if all factors are answered with “no”, the risk for the domain will be high.
44	1. Strongly agree
45	2. Agree
46	3. Disagree
47	4. Strongly disagree
48	5. Can’t say
49	Comments/suggestions:
50	In domain 3 , if all factors of high importance are answered with “no”, the risk for the domain will
51	be high.
52	1. Strongly agree
53	2. Agree
54	3. Disagree
55	4. Strongly disagree
56	5. Can’t say
57	Comments/suggestions:
58	In domain 3 , if all factors of high importance are answered with “no”, the risk for the domain will
59	be high.
60	

1	1. Strongly agree
2	2. Agree
3	3. Disagree
4	4. Strongly disagree
5	5. Can't say
6	Comments/suggestions:
7	In domain 3 , if at least 1 factor is answered with "no", the risk for the domain will be high.
8	1. Strongly agree
9	2. Agree
10	3. Disagree
11	4. Strongly disagree
12	5. Can't say
13	Comments/suggestions:
14	In domain 3 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
15	1. Strongly agree
16	2. Agree
17	3. Disagree
18	4. Strongly disagree
19	5. Can't say
20	Comments/suggestions:
21	In domain 3 , if at least 2 factors are answered with "no", the risk for the domain will be high.
22	1. Strongly agree
23	2. Agree
24	3. Disagree
25	4. Strongly disagree
26	5. Can't say
27	Comments/suggestions:
28	In domain 3 , if at least 2 factors of high importance are answered with "no", the risk for the domain will be high.
29	1. Strongly agree
30	2. Agree
31	3. Disagree
32	4. Strongly disagree
33	5. Can't say
34	Comments/suggestions:
35	Any other suggestions about stratifying risk in domain 3?
36	Domain 4 – Postoperative surveillance
37	In domain 4 , if all factors are answered with "yes", the risk for the domain will be low.
38	1. Strongly agree
39	2. Agree
40	3. Disagree
41	4. Strongly disagree
42	5. Can't say
43	Comments/suggestions:
44	In domain 4 , if all factors of high importance are answered with "yes", the risk for the domain will be low.
45	1. Strongly agree
46	2. Agree
47	3. Disagree
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1	4. Strongly disagree
2	5. Can't say
3	Comments/suggestions:
4	In domain 4 , if all factors are answered with "no", the risk for the domain will be high.
5	1. Strongly agree
6	2. Agree
7	3. Disagree
8	4. Strongly disagree
9	5. Can't say
10	Comments/suggestions:
11	In domain 4 , if all factors of high importance are answered with "no", the risk for the domain will be high.
12	1. Strongly agree
13	2. Agree
14	3. Disagree
15	4. Strongly disagree
16	5. Can't say
17	Comments/suggestions:
18	In domain 4 , if at least 1 factor is answered with "no", the risk for the domain will be high.
19	1. Strongly agree
20	2. Agree
21	3. Disagree
22	4. Strongly disagree
23	5. Can't say
24	Comments/suggestions:
25	In domain 4 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
26	1. Strongly agree
27	2. Agree
28	3. Disagree
29	4. Strongly disagree
30	5. Can't say
31	Comments/suggestions:
32	In domain 4 , if at least 1 factor of high importance is answered with "no", the risk for the domain will be high.
33	1. Strongly agree
34	2. Agree
35	3. Disagree
36	4. Strongly disagree
37	5. Can't say
38	Comments/suggestions:
39	Any other suggestions about risk stratification in domain 4?
40	
41	Risk stratification
42	If the risk in all domains is low, the overall risk should be low.
43	1. Strongly agree
44	2. Agree
45	3. Disagree
46	4. Strongly disagree
47	5. Can't say
48	Comments/suggestions:
49	If the risk in all domains is high, the overall risk should be high.
50	1. Strongly agree
51	2. Agree
52	3. Disagree
53	4. Strongly disagree
54	5. Can't say
55	Comments/suggestions:
56	If the risk in at least 1 domain is high, the overall risk should be low.
57	
58	
59	
60	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<ol style="list-style-type: none">1. Strongly agree2. Agree3. Disagree4. Strongly disagree5. Can't say
Comments/suggestions:
Any other suggestions about the overall risk stratification?

Appendix 2. Tier 2 survey: Defining the risk stratification model.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surveillance strategies should be risk specific, e.g. patients that have been judged to be high risk for developing adverse events after EVAR should have different surveillance than low risk patients.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Low risk

For **low risk** patients, surveillance should be with US and X-ray annually, with a CT angiogram at 5 years, unless there is sac expansion and/or migration, when CT should be performed.

6. Strongly agree
7. Agree
8. Disagree
9. Strongly disagree
10. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US and X-ray annually, with a CT angiogram only if there is sac expansion and/or migration.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

For **low risk** patients, surveillance should be with US annually, with a CT angiogram only if there is sac expansion.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Low risk patients should have no surveillance at all.

1. Strongly agree
2. Agree
3. Disagree
4. Strongly disagree
5. Can't say

Comments/suggestions:

Any other suggestions about surveillance strategies in low risk patients?

1	
2	
3	
4	Intermediate risk
5	Intermediate risk patients should have the same surveillance as low risk patients.
6	1. Strongly agree
7	2. Agree
8	3. Disagree
9	4. Strongly disagree
10	5. Can't say
11	Comments/suggestions:
12	Intermediate risk patients should have the same surveillance as high risk patients.
13	1. Strongly agree
14	2. Agree
15	3. Disagree
16	4. Strongly disagree
17	5. Can't say
18	Comments/suggestions:
19	Any other suggestions about surveillance strategies in intermediate risk patients?
20	
21	
22	
23	High risk
24	For high risk patients, surveillance should be with annual CT angiogram.
25	1. Strongly agree
26	2. Agree
27	3. Disagree
28	4. Strongly disagree
29	5. Can't say
30	Comments/suggestions:
31	For high risk patients, surveillance should be with annual CT angiogram and US+X-ray alternately (one year CT, next year US+X-ray).
32	1. Strongly agree
33	2. Agree
34	3. Disagree
35	4. Strongly disagree
36	5. Can't say
37	Comments/suggestions:
38	For high risk patients, surveillance should be with annual CT angiogram and US alternately (one year CT, next year US).
39	1. Strongly agree
40	2. Agree
41	3. Disagree
42	4. Strongly disagree
43	5. Can't say
44	Comments/suggestions:
45	For high risk patients, surveillance should be with US and X-ray annually, with a CT angiogram at 5 years, unless there is sac expansion and/or migration, when CT should be performed.
46	1. Strongly agree
47	2. Agree
48	3. Disagree
49	4. Strongly disagree
50	5. Can't say
51	Comments/suggestions:
52	For high risk patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.
53	1. Strongly agree
54	2. Agree
55	3. Disagree
56	4. Strongly disagree
57	5. Can't say
58	Comments/suggestions:
59	For high risk patients, surveillance should be with US annually, with a CT angiogram at 5 years, unless there is sac expansion, when CT should be performed.
60	

<p>1. Strongly agree</p> <p>2. Agree</p> <p>3. Disagree</p> <p>4. Strongly disagree</p> <p>5. Can't say</p> <p>Comments/suggestions:</p>
<p>For high risk patients, surveillance should be with US and X-ray annually, with a CT angiogram only if there is sac expansion and/or migration.</p> <p>1. Strongly agree</p> <p>2. Agree</p> <p>3. Disagree</p> <p>4. Strongly disagree</p> <p>5. Can't say</p> <p>Comments/suggestions:</p>
<p>For high risk patients, surveillance should be with US annually, with a CT angiogram only if there is sac expansion.</p> <p>1. Strongly agree</p> <p>2. Agree</p> <p>3. Disagree</p> <p>4. Strongly disagree</p> <p>5. Can't say</p> <p>Comments/suggestions:</p>
<p>Any other suggestions about surveillance strategies in high risk patients?</p>
<p>What do you think the role of contrast-enhanced US in EVAR surveillance should be (choose one or more)?</p> <p>1. It should always be used instead of standard US.</p> <p>2. It should always be used instead of CT.</p> <p>3. It should be used instead of CT in cases where contraindications to CT exist.</p> <p>4. It should be used only in cases of uncertainty as to the origin of endoleak.</p> <p>5. There is no role.</p> <p>6. Other (please, specify).</p> <p>Comments/suggestions:</p>
<p>What do you think the role of DSA in EVAR surveillance should be?</p> <p>1. It should be used in cases of indeterminate endoleak.</p> <p>2. There is no role.</p> <p>3. Other (please, specify)</p> <p>Comments/suggestions:</p>
<p>What do you think the threshold for sac expansion that should trigger further investigations/interventions should be?</p> <p>1. 5 mm</p> <p>2. 10 mm</p> <p>3. 15 mm</p> <p>4. There should be no threshold; any sac expansion should be acted upon.</p> <p>5. Other (please, specify)</p> <p>Comments/suggestions:</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

What do you think the threshold for graft migration that should trigger further investigations/interventions should be?

1. 5 mm
2. 10 mm
3. 15 mm
4. There should be no threshold; any graft migration should be acted upon.
5. Other (please, specify)

Comments/suggestions:

Appendix 3. Tier 3 survey: Defining endovascular aneurysm repair surveillance strategies. CT, computed tomography; DSA, digital subtraction angiography; EVAR, endovascular aneurysm repair; US, ultrasonography.

For peer review only